Ability to drive

Abacavir/lamivudine [1], ability to drive ---> SmPC of [1] of EMA

The clinical status of the patient and the adverse reaction profile of Kivexa should be borne in mind when considering the patient's ability to drive or operate machinery.

Abacavir/lamivudine/zidovudine [1], ability to drive ---> SmPC of [1] of EMA

The clinical status of the patient and the adverse event profile of Trizivir should be borne in mind when considering the patient's ability to drive or operate machinery.

Abaloparatide [1], ability to drive ---> SmPC of [1] of EMA

Transient orthostatic hypotension or dizziness may occur following administration of abaloparatide (see section 4.8). These patients should refrain from driving or the use of machines until symptoms have subsided.

Abatacept [1], ability to drive ---> SmPC of [1] of EMA

Dizziness and reduced visual acuity may occur

Abemaciclib [1], ability to drive ---> SmPC of [1] of EMA

Patients should be advised to be cautious when driving or using machines in case they experience fatigue or dizziness during treatment with Verzenios

Ability to drive [1], NSAID ---> SmPC of [1] of eMC

Dizziness, drowsiness, fatigue and visual disturbances may occur

Ability to drive [1], St. John's wort ---> SmPC of [1] of eMC

In rare cases St John's Wort may make you feel dizzy or sleepy. If affected do not drive or use machines.

Ability to drive [1], Zalmoxis 5-20 x 10^6 cells/mL dispersion for infusion ---> SmPC of [1] of EMA

The clinical status of the patient and the ADR profile of Zalmoxis should be born in mind when considering the patient's ability to perform tasks that require judgement, motor or cognitive skills.

Ability to drive, abiraterone/niraparib [2] ---> SmPC of [2] of EMA

Akeega has moderate influence on the ability to drive or use machines. Patients who take Akeega may experience asthenia, fatigue, dizziness or difficulties concentrating. Patients should use caution when driving or using machines.

Ability to drive, acalabrutinib [2] ---> SmPC of [2] of EMA

However, during treatment with acalabrutinib, fatigue and dizziness have been reported and patients who experience these symptoms should be advised not to drive or use machines until symptoms abate.

Ability to drive, ACE inhibitors ---> SmPC of [trandolapril] of eMC

ACE inhibitors may affect the ability to drive or operate machinery, particularly at the start of treatment, when changing over from other medication or during concomitant use of alcohol.

Ability to drive, aceclofenac [2] ---> SmPC of [2] of eMC

Undesirable effects such as dizziness, drowsiness, vertigo, fatigue, visual disturbances or other central nervous system disorders are possible after taking NSAIDs. If affected, patients should not drive or operate machinery

Ability to drive, acetazolamide [2] ---> SmPC of [2] of eMC

Drowsiness and/or paraesthesia may occur

Ability to drive, acetylcholine

The surgical procedure may impair vision.

Ability to drive, acetylcysteine

Somnolence may occur

Ability to drive, aciclovir

Headache and dizziness may occur

Ability to drive, acitretin [2] ---> SmPC of [2] of eMC

Decreased night vision has been reported with Acitretin therapy.

Ability to drive, aclidinium [2] ---> SmPC of [2] of EMA

Aclidinium bromide may have minor influence on the ability to drive and use machines. The occurrence of headache, dizziness or blurred vision following administration of aclidinium bromide may influence the ability to drive or to use machinery.

Ability to drive, aclidinium/formoterol [2] ---> SmPC of [2] of EMA

The occurrence of blurred vision or dizziness may influence the ability to drive or to use machines.

Ability to drive, acrivastine

Do not undertake tasks requiring mental alertness

Ability to drive, adalimumab [2] ---> SmPC of [2] of EMA

Vertigo and visual impairment may occur following administration of Humira

Ability to drive, adrenaline [2] ---> SmPC of [2] of eMC

Not applicable; this preparation is intended for use only in emergencies.

Ability to drive, adsorbed diphtheria vaccine

Visual disturbances and circulation problems may occur

Ability to drive, afamelanotide [2] ---> SmPC of [2] of EMA

Following administration of this medicinal product, somnolence, fatigue, dizziness, and nausea have been reported.

Ability to drive, afatinib [2] ---> SmPC of [2] of EMA

During treatment, ocular adverse reactions (conjunctivitis, dry eye, keratitis) have been reported in some patients

Ability to drive, aflibercept [2] ---> SmPC of [2] of EMA

Possible temporary visual disturbances associated either with the injection or the eye examination.

Ability to drive, agalsidase beta [2] ---> SmPC of [2] of EMA

Agalsidase beta may have a minor influence on the ability to drive or use machines on the day of agalsidase beta administration because dizziness, somnolence, vertigo and syncope may occur

Ability to drive, agomelatine [2] ---> SmPC of [2] of EMA

Considering that dizziness and somnolence are common adverse reactions patients should be cautioned about their ability to drive a car or operate machinery.

Ability to drive, ajmaline

This drug may affect the ability to drive or operate machines

Ability to drive, albiglutide [2] ---> SmPC of [2] of EMA

When Eperzan is used in combination with insulin secretagogues (such as sulphonylureas) or insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines

Ability to drive, aldesleukin [2] ---> SmPC of [2] of eMC

Hallucination, somnolence, syncope, convulsions may occur during treatment with Proleukin and may affect the patient's ability to drive and operate machines.

Ability to drive, alectinib [2] ---> SmPC of [2] of EMA

Caution should be exercised when driving or operating machines as patients may experience symptomatic bradycardia (e.g., syncope, dizziness, hypotension) or vision disorders while taking Alecensa

Ability to drive, alemtuzumab [2] ---> SmPC of [2] of EMA

Most patients experience infusion-associated reactions (IARs) which occur during or within 24 hours after treatment. Some of the IARs (e.g. dizziness) could temporarily impact the patient's ability to drive or use machines

Ability to drive, alendronate

Dizziness or vertigo may occur

Ability to drive, alendronate/colecalciferol [2] ---> SmPC of [2] of EMA

ADROVANCE may have a moderate influence on the ability to drive and use machines in patients that experience certain adverse reactions (for example blurred vision, dizziness and severe bone muscle or joint pain

Ability to drive, alendronic acid/colecalciferol [2] ---> SmPC of [2] of EMA

Certain adverse reactions (for example blurred vision, dizziness and severe bone muscle or joint pain) have been reported

Ability to drive, alfentanyl [2] ---> SmPC of [2] of eMC

Not to drive or operate machinery for at least 3-6 or 12-24 hours following administration.

Ability to drive, alfuzosin [2] ---> SmPC of [2] of eMC

Vertigo, dizziness and asthenia may occur.

Ability to drive, alglucosidase alfa [2] ---> SmPC of [2] of EMA

Because dizziness has been reported as an infusion associated reaction, this may affect the ability to drive and use machines on the day of the infusion.

Ability to drive, alimemazine [2] ---> SmPC of [2] of eMC

Drowsiness may occur

Ability to drive, alipogene tiparvovec [2] ---> SmPC of [2] of EMA

Dizziness was commonly observed after alipogen tiparvovec administration

Ability to drive, aliskiren [2] ---> SmPC of [2] of EMA

When driving vehicles or operating machinery it must be borne in mind that dizziness or weariness may occasionally occur when taking Rasilez.

Ability to drive, aliskiren/amlodipine [2] ---> SmPC of [2] of EMA

When driving vehicles or using machines it must be borne in mind that dizziness or drowsiness may occasionally occur when taking Rasilamlo.

Ability to drive, aliskiren/amlodipine/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

When driving vehicles or using machines it must be borne in mind that dizziness or drowsiness may occasionally occur when taking Rasitrio.

Ability to drive, aliskiren/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

When driving vehicles or operating machinery it must be borne in mind that dizziness or drowsiness may occasionally occur when taking Rasilez HCT.

Ability to drive, alitretinoin [2] ---> SmPC of [2] of eMC

Decreased night vision has been reported in patients treated with alitretinoin and other retinoids.

Ability to drive, alizapride

Somnolence may occur

Ability to drive, allopurinol [2] ---> SmPC of [2] of eMC

Adverse reactions such as somnolence, vertigo and ataxia have been reported in patients receiving allopurinol

Ability to drive, allopurinol/lesinurad [2] ---> SmPC of [2] of EMA

Somnolence, vertigo and ataxia have been reported in patients receiving allopurinol

Ability to drive, almotriptan [2] ---> SmPC of [2] of eMC

Since somnolence may occur during a migraine attack and has been reported as a side effect of treatment with almotriptan, caution is recommended in patients performing skilled tasks.

Ability to drive, alogliptin [2] ---> SmPC of [2] of EMA

Patients should be alerted to the risk of hypoglycaemia

Ability to drive, alogliptin/metformin [2] ---> SmPC of [2] of EMA

Patients should be alerted to the risk of hypoglycaemia

Ability to drive, alogliptin/pioglitazone [2] ---> SmPC of [2] of EMA

Patients who experience visual disturbance should be cautious when driving or using machines.

Ability to drive, alpelisib [2] ---> SmPC of [2] of EMA

Patients should be advised to be cautious when driving or using machines in case they experience fatigue or blurred vision during treatment

Ability to drive, alprazolam [2] ---> SmPC of [2] of eMC

Sedation, amnesia, impaired concentration and impaired muscle function may adversely affect the ability to drive or use machines.

Ability to drive, alprostadil

Hypotension or syncope may occur.

Ability to drive, amantadine [2] ---> SmPC of [2] of eMC

Patients should be warned of the potential hazards of driving or operating machinery if they experience side effects such as dizziness or blurred vision.

Ability to drive, ambrisentan [2] ---> SmPC of [2] of EMA

Patients should be aware of how they might be affected by ambrisentan before driving or using machines.

Ability to drive, amfepramone

Changes in the ability to react

Ability to drive, amifampridine [2] ---> SmPC of [2] of EMA

Due to adverse reactions such as drowsiness, dizziness, seizures and blurred vision, amifampridine may have minor or moderate influence on the ability to drive or use machines

Ability to drive, amikacine [2] ---> SmPC of [2] of eMC

Due to the occurrence of some adverse reactions the ability to drive and use machinery may be impaired.

Ability to drive, amiloride/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Infrequently, patients may experience weakness, fatigue, dizziness, stupor and vertigo. Should any of these occur, the patient should be cautioned not to drive or operate machinery.

Ability to drive, aminophylline

None stated.

Ability to drive, amisulpride [2] ---> SmPC of [2] of eMC

Even used as recommended, amisulpride may cause somnolence so that the ability to drive vehicles or operate machinery can be impaired

Ability to drive, amitriptyline [2] ---> SmPC of [2] of eMC

Amitriptyline may initially impair alertness. Patients should be warned of the performance of potentially hazardous tasks such as driving a car or operating machinery.

Ability to drive, amivantamab [2] ---> SmPC of [2] of EMA

If patients experience treatment-related symptoms, including vision-related adverse reactions, affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides.

Ability to drive, amlodipine

Dizziness, headache, fatigue or nausea may occur

Ability to drive, amlodipine/valsartan [2] ---> SmPC of [2] of EMA

Patients taking Dafiro and driving vehicles or using machines should take into account that dizziness or weariness may occasionally occur.

Ability to drive, amlodipine/valsartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Patients taking Dafiro HCT and driving vehicles or using machines should take into account that dizziness or weariness may occasionally occur.

Ability to drive, amoxicillin/clavulanic acid [2] ---> SmPC of [2] of eMC

Undesirable effects may occur (e.g. allergic reactions, dizziness, convulsions), which may influence the ability to drive and use machines

Ability to drive, anagrelide [2] ---> SmPC of [2] of EMA

Dizziness may occur

Ability to drive, anastrozole [2] ---> SmPC of [2] of eMC

Asthenia and somnolence have been reported with the use of anastrozole

Ability to drive, antihypertensives

It should be taken into account that occasionally dizziness or asthenia may occur during treatment with hypotensive medicinal products

Ability to drive, antimuscarinic agents

Dizziness, blurred vision, insomnia and somnolence may occur

Ability to drive, apalutamide [2] ---> SmPC of [2] of EMA

Seizures have been reported in patients taking Erleada. Patients should be advised of this risk in regards to driving or operating machines.

Ability to drive, apomorphine [2] ---> SmPC of [2] of eMC

Somnolence and/or sudden sleep episodes may occur

Ability to drive, apraclonidine [2] ---> SmPC of [2] of eMC

Since clonidine-like drugs may cause dizziness or somnolence, patients so affected are advised not to drive or operate machinery.

Ability to drive, aprepitant [2] ---> SmPC of [2] of EMA

Dizziness and fatigue may occur following administration of EMEND

Ability to drive, aripiprazole [2] ---> SmPC of [2] of EMA

Potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred may occur

Ability to drive, artemether/lumefantrine [2] ---> SmPC of [2] of eMC

Patients should be warned that dizziness or fatigue/asthenia may occur in which case they should not drive or use machines.

Ability to drive, artesunate [2] ---> SmPC of [2] of EMA

No studies on the effects on the ability to drive and use machines have been performed. Patients should be warned not to drive or use machines if they feel tired or dizzy.

Ability to drive, articaine/epinephrine

The patient should not leave the dental clinic within 30 minutes after the injection

Ability to drive, asciminib [2] ---> SmPC of [2] of EMA

It is recommended that patients experiencing dizziness, fatigue or other undesirable effects with a potential impact on the ability to drive or use machines safely should refrain from these activities as long as the undesirable effects persist.

Ability to drive, asenapine [2] ---> SmPC of [2] of EMA

Asenapine may cause somnolence and sedation. Therefore, patients should be cautioned about driving and using machines until they are reasonably certain that Sycrest therapy does not affect them adversely.

Ability to drive, asparaginase [2] ---> SmPC of [2] of EMA

Spectrila has moderate influence on the ability to drive and use machines, especially through its potential effects on the nervous and gastrointestinal systems

Ability to drive, ataluren [2] ---> SmPC of [2] of EMA

Patients who experience dizziness should use caution when driving, cycling or using machines.

Ability to drive, atazanavir [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness has been reported during treatment with regimens containing REYATAZ

Ability to drive, atazanavir/cobicistat [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness has been reported during treatment with regimens containing atazanavir or cobicistat

Ability to drive, atenolol [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or fatigue may occur.

Ability to drive, atenolol/chlortalidone [2] ---> SmPC of [2] of eMC

It should be taken into account that occasionally dizziness or fatigue may occur.

Ability to drive, atenolol/nifedipine [2] ---> SmPC of [2] of eMC

It should be taken into account that occasionally dizziness or fatigue may occur.

Ability to drive, atezolizumab [2] ---> SmPC of [2] of EMA

Patients experiencing fatigue should be advised not to drive and use machines until symptoms abate

Ability to drive, atidarsagene [2] ---> SmPC of [2] of EMA

The effect of the mobilisation agents and the myeloablative conditioning agent on the ability to drive or use machines must be considered.

Ability to drive, atomoxetine

Atomoxetine was associated with increased rates of fatigue relative to placebo.

Ability to drive, atovaquone/proguanil [2] ---> SmPC of [2] of eMC

Dizziness has been reported.

Ability to drive, atracurium [2] ---> SmPC of [2] of eMC

As the medicinal product is administered under general anaesthesia, the patient must not drive, operate machinery or work in exposed situations after anaesthesia.

Ability to drive, atropine [2] ---> SmPC of [2] of eMC

Atropine may cause drowsiness or blurred vision and patients should be advised of it.

Ability to drive, autologous anti-CD19-transduced CD3+ cells [2] ---> SmPC of [2] of EMA

Due to the potential for neurologic events, including altered mental status/seizures, patients should not drive or operate heavy or potentially dangerous machines until at least 8 weeks after infusion or until resolution of neurologic adverse reactions.

Ability to drive, autologous chondrocyte [2] ---> SmPC of [2] of EMA

Driving cars and using machines may be limited during the rehabilitation period.

Ability to drive, avalglucosidase alfa [2] ---> SmPC of [2] of EMA

Because dizziness, hypotension and somnolence have been reported as IARs, this may affect the ability to drive and use machines on the day of the infusion

Ability to drive, avanafil [2] ---> SmPC of [2] of EMA

As dizziness and altered vision were reported in clinical trials with avanafil, patients should be aware of how they react to Spedra before driving or using machines.

Ability to drive, avapritinib [2] ---> SmPC of [2] of EMA

Patients should be made aware of the potential for adverse reactions that affect their ability to concentrate and react.

Ability to drive, axicabtagene ciloleucel [2] ---> SmPC of [2] of EMA

Due to the potential for neurologic events, patients should refrain from driving or operating heavy or potentially dangerous machines until at least 8 weeks after infusion or until resolution of neurologic adverse reactions.

Ability to drive, axitinib [2] ---> SmPC of [2] of EMA

Axitinib has a minor influence on the ability to drive and use machines. Patients should be advised that they may experience events such as dizziness and/or fatigue during treatment with axitinib.

Ability to drive, azacitidine [2] ---> SmPC of [2] of EMA

Fatigue has been reported with the use of azacitidine. Therefore, caution is recommended when driving or operating machines.

Ability to drive, azelastine [2] ---> SmPC of [2] of eMC

If there are any transient effects on vision, the patient should be advised to wait until this clears before driving or operating machinery.

Ability to drive, azilsartan medoxomil [2] ---> SmPC of [2] of EMA

When taking any antihypertensive it should be taken into account that occasionally dizziness or tiredness may occur.

Ability to drive, azilsartan [2] ---> SmPC of [2] of EMA

You may feel tired or dizzy

Ability to drive, azithromycin [2] ---> SmPC of [2] of eMC

Dizziness and convulsions may occur

Ability to drive, baclofen [2] ---> SmPC of [2] of eMC

The ability to drive or operate machinery may be considerably impaired during treatment with baclofen

Ability to drive, barnidipine

It should be taken into account that occasionally dizziness or vertigo may occur during treatment with hypotensive medicinal products

Ability to drive, bazedoxifene [2] ---> SmPC of [2] of EMA

Patients may experience visual symptoms such as visual acuity disturbance or blurred vision.

Ability to drive, bedaquiline [2] ---> SmPC of [2] of EMA

Adverse reactions, such as dizziness, may affect the ability to drive or use machines.

Ability to drive, belantamab [2] ---> SmPC of [2] of EMA

Patients should be advised to use caution when driving or operating machines as BLENREP may affect their vision.

Ability to drive, belatacept [2] ---> SmPC of [2] of EMA

Belatacept has a minor influence on the ability to drive and use machines since it may cause fatigue, malaise and/or nausea.

Ability to drive, belimumab [2] ---> SmPC of [2] of EMA

The clinical status of the subject and the adverse reaction profile of Benlysta should be borne in mind when considering the patient's ability to perform tasks that require judgement, motor or cognitive skills.

Ability to drive, bempedoic acid/ezetimibe [2] ---> SmPC of [2] of EMA

When driving vehicles or using machines, it should be taken into account that dizziness has been reported with bempedoic acid and ezetimibe

Ability to drive, benazepril

As with other antihypertensives, the ability to drive and use machines may be reduced

Ability to drive, benazepril/hydrochlorothiazide

The ability to drive a vehicle or to operate machinery may be impaired

Ability to drive, bendamustine [2] ---> SmPC of [2] of eMC

Ataxia, peripheral neuropathy and somnolence have been reported during treatment with bendamustine

Ability to drive, benperidol [2] ---> SmPC of [2] of eMC

Benperidol may interfere with activities requiring mental alertness.

Ability to drive, benzodiazepines

The sedative effect affects the ability to drive or use machines

Ability to drive, betablockers

Dizziness or fatigue may occur

Ability to drive, betahistidine

Drowsiness may occur

Ability to drive, betaxolol

Transitory blurred sight or vision disorders may occur

Ability to drive, bethanechol

Dizzy spell, drowsiness, nauseas, hypotension, blurred vision or accommodation disturbances may occur

Ability to drive, bevacizumab [2] ---> SmPC of [2] of EMA

If patients are experiencing symptoms that affect their vision or concentration, or their ability to react, they should be advised not to drive and use machines until symptoms abate.

Ability to drive, bexarotene [2] ---> SmPC of [2] of EMA

Dizziness and visual difficulties may occur

Ability to drive, bicalutamide [2] ---> SmPC of [2] of eMC

It should be noted that occasionally dizziness or somnolence may occur

Ability to drive, bictegravir/emtricitabine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness has been reported during treatment with the components of Biktarvy

Ability to drive, bilastine [2] ---> SmPC of [2] of eMC

Patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.

Ability to drive, bimatoprost [2] ---> SmPC of [2] of EMA

Transient blurred vision may occur

Ability to drive, bimatoprost/timolol [2] ---> SmPC of [2] of EMA

As with any ocular treatment, if transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machines.

Ability to drive, binimetinib [2] ---> SmPC of [2] of EMA

Patients should be advised not to drive or use machines if they experience visual disturbances or any other adverse reaction that may affect their ability to drive and use machines

Ability to drive, biperiden

Fatigue, dizziness and stupor may occur

Ability to drive, bisacodyl [2] ---> SmPC of [2] of eMC

Patients should be advised that due to a vasovagal response (e.g. to abdominal spasm) they may experience dizziness and / or syncope.

Ability to drive, bisoprolol [2] ---> SmPC of [2] of eMC

Depending on the individual patient's response the ability to drive a vehicle or to use machines may be impaired.

Ability to drive, bleomycin [2] ---> SmPC of [2] of eMC

This depends on the patient's condition and should be considered in co-operation with the doctor.

Ability to drive, blinatumomab [2] ---> SmPC of [2] of EMA

Due to the potential for neurologic events, patients receiving blinatumomab should refrain from driving, engaging in hazardous occupations or activities such as driving or operating heavy or potentially dangerous machinery

Ability to drive, boceprevir [2] ---> SmPC of [2] of EMA

Fatigue, dizziness, syncope, blood pressure fluctuations and blurred vision may occur

Ability to drive, bortezomib [2] ---> SmPC of [2] of EMA

VELCADE may be associated with fatigue very commonly, dizziness commonly, syncope uncommonly and orthostatic/postural hypotension or blurred vision commonly.

Ability to drive, bosentan [2] ---> SmPC of [2] of EMA

Tracleer may induce hypotension, with symptoms of dizziness, blurred vision or syncope that could affect the ability to drive or use machines.

Ability to drive, bosutinib [2] ---> SmPC of [2] of EMA

Dizziness, fatigue and visual impairment may occur

Ability to drive, botulinum toxin type A [2] ---> SmPC of [2] of EMA

NUCEIVA has a minor or moderate influence on the ability to drive and use machines. There is a potential risk for asthenia, muscle weakness, dizziness and visual disturbance, which could affect driving and the operation of machinery.

Ability to drive, botulinum toxin type B [2] ---> SmPC of [2] of EMA

Muscle weakness and eye disorders (blurred vision, eyelid ptosis) may occur

Ability to drive, botulinus toxin

Muscle weakness and eye disorders may occur

Ability to drive, brentuximab vedotin [2] ---> SmPC of [2] of EMA

Brentuximab vedotin may have a minor influence on the ability to drive and use machines.

Ability to drive, brexpiprazole [2] ---> SmPC of [2] of EMA

Brexpiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system effects, such as sedation and dizziness that are common adverse drug reactions

Ability to drive, brigatinib [2] ---> SmPC of [2] of EMA

Caution should be exercised when driving or operating machines as patients may experience visual disturbance, dizziness, or fatigue while taking Alunbrig.

Ability to drive, brinzolamide [2] ---> SmPC of [2] of EMA

Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines

Ability to drive, brinzolamide/brimonidine [2] ---> SmPC of [2] of EMA

Brinzolamide/brimonidine may cause dizziness, fatigue and/or drowsiness, which may impair the ability to drive or use machines.

Ability to drive, brinzolamide/timolol [2] ---> SmPC of [2] of EMA

Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines.

Ability to drive, brivaracetam [2] ---> SmPC of [2] of EMA

Due to possible differences in individual sensitivity some patients might experience somnolence, dizziness, and other central nervous system (CNS) related symptoms.

Ability to drive, brivudine

Dizziness and somnolence may occur

Ability to drive, brolucizumab [2] ---> SmPC of [2] of EMA

Patients should not drive or use machines until visual function has recovered sufficiently.

Ability to drive, bromazepam

Sedation, amnesia, decreased concentration ability and impaired muscular function may occur

Ability to drive, bromfenac [2] ---> SmPC of [2] of EMA

Transient blurring of vision may occur on instillation

Ability to drive, bromhexine

Dizziness may occur

Ability to drive, bromocriptine [2] ---> SmPC of [2] of eMC

Hypotensive reactions may be disturbing in some patients during the first few days of treatment and particular care should be exercised when driving vehicles or operating machinery.

Ability to drive, bromperidol

Drowsiness may occur

Ability to drive, brotizolam

Brotizolam may cause somnolence

Ability to drive, budipine

Changes in the ability to react

Ability to drive, buflomedil

Vertigo or dizziness may occur

Ability to drive, bulevirtide [2] ---> SmPC of [2] of EMA

The product has minor influence on the ability to drive and use machines. Patients should be informed that dizziness has been reported during treatment with bulevirtide.

Ability to drive, bupivacaine [2] ---> SmPC of [2] of eMC

Depending on dosage, local anaesthetics may have a very mild effect on mental function and co-ordination even in the absence of overt CNS toxicity and may temporarily impair locomotion and alertness.

Ability to drive, bupivacaine/meloxicam [2] ---> SmPC of [2] of EMA

Zynrelef may have a very mild effect on mental function and coordination even in the absence of overt central nervous system (CNS) toxicity, and may temporarily impair locomotion and alertness.

Ability to drive, buprenorphine [2] ---> SmPC of [2] of EMA

The patient should be cautioned not to drive or operate hazardous machinery whilst taking this medicine until it is known how the patient is affected by the medicine.

Ability to drive, buprenorphine/naloxone [2] ---> SmPC of [2] of EMA

This product may cause drowsiness, dizziness, or impaired thinking

Ability to drive, bupropion [2] ---> SmPC of [2] of eMC

As with other CNS acting drugs bupropion may affect ability to perform tasks that require judgement or motor and cognitive skills. Bupropion has also been reported to cause dizziness and lightheadedness.

Ability to drive, burosumab [2] ---> SmPC of [2] of EMA

Burosumab may have a minor influence on the ability to drive and use machines. Dizziness may occur following administration of burosumab.

Ability to drive, buserelin [2] ---> SmPC of [2] of eMC

Certain adverse effects (e.g. dizziness) may impair the ability to concentrate and react

Ability to drive, buspirone [2] ---> SmPC of [2] of eMC

Buspirone has moderate influence on the ability to drive and use machines. Attention is drawn to the risks associated with drowsiness or dizziness induced by this drug

Ability to drive, butylscopolamine [2] ---> SmPC of [2] of eMC

Patients should be advised that they may experience undesirable effects such as accommodation disorder or dizziness during treatment

Ability to drive, cabazitaxel [2] ---> SmPC of [2] of EMA

Cabazitaxel may influence the ability to drive and use machines as it may cause fatigue and dizziness.

Ability to drive, cabergoline [2] ---> SmPC of [2] of eMC

Patients being treated with cabergoline and presenting with somnolence and/or sudden sleep onset episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk

Ability to drive, cabotegravir [2] ---> SmPC of [2] of EMA

The clinical status of the patient and the adverse reaction profile of Vocabria injection should be borne in mind when considering the patient's ability to drive or operate machinery.

Ability to drive, cabozantinib [2] ---> SmPC of [2] of EMA

Adverse reactions such as fatigue and weakness have been associated with cabozantinib.

Ability to drive, calcitonin preparations [2] ---> SmPC of [2] of EMA

May cause transient dizziness

Ability to drive, canagliflozin [2] ---> SmPC of [2] of EMA

Patients should be alerted to the risk of hypoglycaemia when canagliflozin is used as add-on therapy with insulin or an insulin secretagogue, and to the elevated risk of adverse reactions related to volume depletion, such as postural dizziness

Ability to drive, canagliflozin/metformin [2] ---> SmPC of [2] of EMA

Patients should be alerted to the risk of hypoglycaemia when Vokanamet is used as add-on therapy with insulin or an insulin secretagogue, and to the elevated risk of adverse reactions related to volume depletion, such as postural dizziness

Ability to drive, canakinumab [2] ---> SmPC of [2] of EMA

Ilaris has minor influence on the ability to drive and use machines. Treatment with Ilaris may result in dizziness/vertigo or asthenia

Ability to drive, candesartan cilexetil [2] ---> SmPC of [2] of eMC

It should be taken into account that occasionally dizziness or weariness may occur during treatment with candesartan cilexetil.

Ability to drive, candesartan [2] ---> SmPC of [2] of eMC

It should be taken into account that occasionally dizziness or weariness may occur during treatment with candesartan cilexetil.

Ability to drive, cannabidiol [2] ---> SmPC of [2] of EMA

Cannabidiol has major influence on the ability to drive and operate machines because it may cause somnolence and sedation

Ability to drive, capecitabine [2] ---> SmPC of [2] of EMA

Capecitabine may cause dizziness, fatigue and nausea.

Ability to drive, captopril [2] ---> SmPC of [2] of eMC

As with other antihypertensives, the ability to drive and use machines may be reduced

Ability to drive, carbamazepine [2] ---> SmPC of [2] of eMC

The patient's ability to react may be impaired by the medical condition resulting in seizures and adverse reactions including dizziness, drowsiness, ataxia, diplopia, impaired accommodation and blurred vision

Ability to drive, carbidopa

Carbidopa may cause dizziness and orthostatic hypotension

Ability to drive, carboplatin [2] ---> SmPC of [2] of eMC

Carboplatin may cause nausea and vomiting, indirectly impairing the ability to drive and use machines.

Ability to drive, carfilzomib [2] ---> SmPC of [2] of EMA

Fatigue, dizziness, fainting, blurred vision, somnolence and/or a drop in blood pressure have been observed in clinical trials.

Ability to drive, cariprazine [2] ---> SmPC of [2] of EMA

Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with Reagila does not affect them adversely.

Ability to drive, carisoprodol

Carisoprodol may cause somnolence

Ability to drive, carmellose

Transitory blurred vision may occur

Ability to drive, carmustine [2] ---> SmPC of [2] of EMA

The possibility will have to be taken into consideration, that the alcohol quantity in these pharmaceutical medicines can impair the ability to drive and use machines.

Ability to drive, carteolol [2] ---> SmPC of [2] of eMC

As with any other eye medication, should a patient experience any disturbance of vision, dizziness or syncope following instillation of carteolol eye drops, driving and the operation of machinery must be avoided

Ability to drive, carvedilol [2] ---> SmPC of [2] of eMC

Some individuals may have reduced alertness especially on initiation and adjustment of medication.

Ability to drive, cathine

Changes in the ability to react

Ability to drive, catumaxomab [2] ---> SmPC of [2] of EMA

Patients experiencing infusion-related symptoms should be advised not to drive and use machines until symptoms abate.

Ability to drive, cefaclor

Insomnia or somnolentia, nervousness, hyperactivity, confusion, hallucinations or dizziness may occur

Ability to drive, cefadroxil [2] ---> SmPC of [2] of eMC

Cefadroxil may cause headache, dizziness, nervousness, sleeplessness and fatigue,

Ability to drive, cefixime

Headaches or dizziness may occur

Ability to drive, cefotaxime [2] ---> SmPC of [2] of eMC

Cefotaxime has been associated with dizziness

Ability to drive, cefpodoxime [2] ---> SmPC of [2] of eMC

Attention should be drawn to the risk of dizzy sensations.

Ability to drive, ceftarolin fosamil [2] ---> SmPC of [2] of EMA

Dizziness may occur and this may have an effect on driving and use of machines

Ability to drive, ceftazidime [2] ---> SmPC of [2] of eMC

Undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines

Ability to drive, ceftazidime/avibactam [2] ---> SmPC of [2] of EMA

Undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines following administration of Zavicefta

Ability to drive, ceftolozane/tazobactam [2] ---> SmPC of [2] of EMA

Dizziness may occur following administration of Zerbaxa

Ability to drive, ceftriaxone [2] ---> SmPC of [2] of eMC

Since ceftriaxone sometimes induces dizziness the ability to drive and use machines can be impaired.

Ability to drive, cefuroxime [2] ---> SmPC of [2] of eMC

As this medicine may cause dizziness, patients should be warned to be cautious when driving or operating machinery.

Ability to drive, celecoxib [2] ---> SmPC of [2] of EMA

Dizziness, vertigo or somnolence may occur

Ability to drive, celiprolol [2] ---> SmPC of [2] of eMC

It should be taken into account that occasional dizziness or fatigue may occur as well as the potential for tremor, headaches or impaired vision.

Ability to drive, cemiplimab [2] ---> SmPC of [2] of EMA

Cemiplimab has no or negligible influence on the ability to drive and use machines. Fatigue has been reported following treatment with cemiplimab

Ability to drive, cenegermin [2] ---> SmPC of [2] of EMA

If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machines.

Ability to drive, cenobamate [2] ---> SmPC of [2] of EMA

Cenobamate may cause somnolence, dizziness, fatigue, impaired vision and other CNS-related symptoms, which may influence the ability to drive or use machines.

Ability to drive, central European encephalitis virus vaccine

Vision disorders or dizziness may occur

Ability to drive, ceritinib [2] ---> SmPC of [2] of EMA

Caution should be exercised when driving or using machines during treatment as patients may experience fatigue or vision disorders.

Ability to drive, certolizumab pegol [2] ---> SmPC of [2] of EMA

Dizziness (including vertigo, vision disorder and fatigue) may occur following administration of Cimzia

Ability to drive, cetuximab [2] ---> SmPC of [2] of EMA

Decreased ability to concentrate and to react may occur

Ability to drive, chloral hydrate [2] ---> SmPC of [2] of eMC

Patients receiving chloral hydrate oral solution should be warned that their ability to drive or use machinery may be impaired by drowsiness.

Ability to drive, chlorambucil

Movement disorder like tremor, twitching and myoclonia may occur

Ability to drive, chlordiazepoxide [2] ---> SmPC of [2] of eMC

Patients should be advised that sedation, amnesia, impaired concentration, dizziness, blurred vision and impaired muscular function may occur

Ability to drive, chloroquine [2] ---> SmPC of [2] of eMC

Defects in visual accommodation may occur on first taking chloroquine and patients should be warned regarding driving or operating machinery.

Ability to drive, chlorphenamine [2] ---> SmPC of [2] of eMC

The anticholinergic properties of chlorphenamine may cause drowsiness, dizziness, blurred vision and psychomotor impairment

Ability to drive, chlorpromazine [2] ---> SmPC of [2] of eMC

Patients should be warned about drowsiness during the early days of treatment and advised not to drive or operate machinery.

Ability to drive, chlorprothixene

Changes in the ability to react

Ability to drive, chlortalidone [2] ---> SmPC of [2] of eMC

Patients should be warned of the potential hazards of driving or operating machinery if they experience side effects such as dizziness.

Ability to drive, chlortetracycline

Transitory blurred sight or vision disorders may occur

Ability to drive, cidofovir [2] ---> SmPC of [2] of EMA

Adverse reactions such as asthenia may occur during cidofovir therapy.

Ability to drive, cilazapril [2] ---> SmPC of [2] of eMC

When driving and operating machines, it should be taken into account that occasionally dizziness and fatigue may occur, especially when starting therapy

Ability to drive, cilostazol [2] ---> SmPC of [2] of EMA

Cilostazol may cause dizziness

Ability to drive, ciltacabtagene autoleucel [2] ---> SmPC of [2] of EMA

Due to the potential for neurologic events, patients receiving CARVYKTI are at risk for altered or decreased consciousness or coordination in the 8 weeks following CARVYKTI infusion (see section 4.4).

Ability to drive, cinacalcet [2] ---> SmPC of [2] of EMA

Certain adverse reactions may affect the ability to drive and use machines

Ability to drive, cinitapride

Reduced mental alertness

Ability to drive, cinnarizine [2] ---> SmPC of [2] of eMC

Cinnarizine may cause drowsiness

Ability to drive, cipaglucosidase alfa [2] ---> SmPC of [2] of EMA

Dizziness, hypotension, and somnolence have been reported as adverse reactions. Caution is required when driving or using any tools or machines after receiving cipaglucosidase alfa.

Ability to drive, ciprofibrate [2] ---> SmPC of [2] of eMC

Dizziness, somnolence, and fatigue have only rarely been reported in association with ciprofibrate.

Ability to drive, ciprofloxacin [2] ---> SmPC of [2] of eMC

Due to its neurological effects, ciprofloxacin may affect reaction time. Thus, the ability to drive or to operate machinery may be impaired.

Ability to drive, cisapride

Do not undertake tasks requiring mental alertness

Ability to drive, cisatracurium [2] ---> SmPC of [2] of eMC

Cisatracurium will always be used in combination with a general anaesthetic and therefore the usual precautions relating to performance of tasks following general anaesthesia apply.

Ability to drive, cisplatin [2] ---> SmPC of [2] of eMC

The profile of undesirable effects (like nephrotoxicity) may influence the ability to drive vehicles and use machinery.

Ability to drive, citalopram [2] ---> SmPC of [2] of eMC

Psychoactive medicinal products can reduce the ability to make judgments and to react to emergencies.

Ability to drive, cladribine [2] ---> SmPC of [2] of EMA

In case certain adverse reactions with a potential impact on performance occur (e.g. dizziness, very common, or drowsiness, which may occur due to anaemia, which is very common), patients should be advised not to drive or use machines.

Ability to drive, clarithromycin [2] ---> SmPC of [2] of eMC

The potential for dizziness, vertigo, confusion and disorientation, which may occur with the medication, should be taken into account before patients drive or use machines.

Ability to drive, clebopride

Do not undertake tasks requiring mental alertness

Ability to drive, clindamycin

Dizziness, somnolence and headache may occur

Ability to drive, clobazam [2] ---> SmPC of [2] of eMC

Sedation, amnesia, impaired concentration and impaired muscular function may adversely affect the ability to drive or to use machines.

Ability to drive, clofarabine [2] ---> SmPC of [2] of EMA

Undesirable effects such as dizziness, light-headedness or fainting spells may occur

Ability to drive, clomiphene [2] ---> SmPC of [2] of eMC

Patients should be warned that visual symptoms may render such activities as driving a car or operating machinery more hazardous than usual, particularly under conditions of variable lighting.

Ability to drive, clomipramine [2] ---> SmPC of [2] of eMC

Patients receiving clomipramine should be warned that blurred vision, drowsiness and other nervous system and psychiatric related disorders have been observed.

Ability to drive, clonazepam [2] ---> SmPC of [2] of eMC

Even when adequately controlled on clonazepam, it should be remembered that any increase in dosage or alteration in timings of dosage may modify patients' reactions, depending on individual susceptibility.

Ability to drive, clonidine [2] ---> SmPC of [2] of eMC

Patients should be advised that they may experience undesirable effects such as dizziness, sedation and accommodation disorder during treatment

Ability to drive, cloperastine

Somnolence may occur

Ability to drive, clozapine [2] ---> SmPC of [2] of eMC

Owing to the ability of clozapine to cause sedation and lower the seizure threshold, activities such as driving or operating machinery should be avoided, especially during the initial weeks of treatment.

Ability to drive, cobimetinib [2] ---> SmPC of [2] of EMA

Patients should be advised not to drive or use machines if they experience visual disturbances or any other adverse effects that may affect their ability.

Ability to drive, codeine [2] ---> SmPC of [2] of eMC

Codeine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.

Ability to drive, codergocrin

Decreased ability to react

Ability to drive, colistimethate [2] ---> SmPC of [2] of EMA

Based on the safety profile of colistimethate sodium, neurotoxity may occur with the possibility of dizziness, confusion or visual disturbances.

Ability to drive, collagenase clostridium histolyticum [2] ---> SmPC of [2] of EMA

Patients must be instructed to avoid potentially hazardous tasks such as driving or using machines until it is safe to do so or as advised by the physician.

Ability to drive, conestat alfa [2] ---> SmPC of [2] of EMA

Headache or vertigo have been reported

Ability to drive, conjugated oestrogens/bazedoxifene [2] ---> SmPC of [2] of EMA

In clinical trials with bazedoxifene monotherapy, somnolence was reported as an adverse reaction. In patients receiving bazedoxifene monotherapy there have been post-marketing reports of visual symptoms such as visual acuity disturbance or blurred vision

Ability to drive, corifollitropin alfa [2] ---> SmPC of [2] of EMA

May cause dizziness

Ability to drive, COVID-19 mRNA vaccine [2] ---> SmPC of [2] of EMA

Some of the effects mentioned under section 4.8 may temporarily affect the ability to drive or use machines.

Ability to drive, COVID-19 vaccine [2] ---> SmPC of [2] of EMA

Nuvaxovid has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section 4.8 may temporarily affect the ability to drive or use machines.

Ability to drive, crizanlizumab [2] ---> SmPC of [2] of EMA

Adakveo may have a minor influence on the ability to drive and use machines. Dizziness, fatigue and somnolence may occur following administration of crizanlizumab.

Ability to drive, crizotinib [2] ---> SmPC of [2] of EMA

Caution should be exercised when driving or operating machines as patients may experience symptomatic bradycardia (e.g., syncope, dizziness, hypotension), vision disorder, or fatigue while taking XALKORI

Ability to drive, cyclopentolate [2] ---> SmPC of [2] of eMC

May cause blurred vision, difficulty in focussing and sensitivity to light.

Ability to drive, cyclophosphamide [2] ---> SmPC of [2] of eMC

None known.

Ability to drive, cyproheptadine [2] ---> SmPC of [2] of eMC

This product may cause drowsiness and somnolence.

Ability to drive, cyproterone [2] ---> SmPC of [2] of eMC

Fatigue and lassitude are common - patients should be warned about this and if affected should not drive or operate machinery.

Ability to drive, cysteamine [2] ---> SmPC of [2] of EMA

Cysteamine may cause drowsiness.

Ability to drive, dabrafenib [2] ---> SmPC of [2] of EMA

Patients should be made aware of the potential for fatigue and eye problems

Ability to drive, dacarbazine [2] ---> SmPC of [2] of eMC

Dacarbazine may influence the ability to drive or operate machines because of its central nervous side effects or because of nausea and vomiting.

Ability to drive, daclatasvir [2] ---> SmPC of [2] of EMA

Dizziness has been reported during treatment with Daklinza in combination with sofosbuvir, and dizziness, disturbance in attention, blurred vision and reduced visual acuity have been reported during treatment with Daklinza in combination with peginterfer

Ability to drive, dacomitinib [2] ---> SmPC of [2] of EMA

Patients experiencing fatigue or ocular adverse reactions while taking dacomitinib should exercise caution when driving or operating machinery.

Ability to drive, dalbavancin [2] ---> SmPC of [2] of EMA

Dizziness has been reported in a small number of patients

Ability to drive, dantrolene [2] ---> SmPC of [2] of eMC

Patients should be advised not to drive a motor vehicle or undertake potentially dangerous work until dantrolene therapy has been stabilised, because some patients experience drowsiness and dizziness.

Ability to drive, dapagliflozin [2] ---> SmPC of [2] of EMA

Take precautions to avoid hypoglycaemia whilst driving or operating machinery

Ability to drive, dapagliflozin/metformin [2] ---> SmPC of [2] of EMA

Patients should be alerted to the risk of hypoglycaemia

Ability to drive, dapiprazole

Dapiprazole causes myosis after topical ocular use

Ability to drive, dapoxetine [2] ---> SmPC of [2] of eMC

Dizziness, disturbances in attention, syncopes, blurred vision and somnolence have been reported

Ability to drive, dapsone [2] ---> SmPC of [2] of eMC

None known.

Ability to drive, daptomycin [2] ---> SmPC of [2] of EMA

On the basis of reported adverse drug reactions, Cubicin is presumed to be unlikely to produce an effect on the ability to drive or use machinery.

Ability to drive, daratumumab [2] ---> SmPC of [2] of EMA

Fatigue has been reported in patients taking daratumumab and this should be taken into account when driving or using machines.

Ability to drive, daridorexant [2] ---> SmPC of [2] of EMA

Hypnotics have a major influence on the ability to drive and use machines. In order to minimise this risk, a period of approximately 9 hours is recommended between taking QUVIVIQ and driving or using machines.

Ability to drive, darifenacin [2] ---> SmPC of [2] of EMA

As with other antimuscarinic agents, Emselex may produce effects such as dizziness, blurred vision, insomnia and somnolence.

Ability to drive, darunavir [2] ---> SmPC of [2] of EMA

Dizziness has been reported in some patients during treatment with regimens containing PREZISTA co-administered with cobicistat or low dose ritonavir and should be borne in mind when considering a patient's ability to drive or operate machinery

Ability to drive, darunavir/cobicistat [2] ---> SmPC of [2] of EMA

Dizziness has been reported in some patients during treatment with regimens containing darunavir administered with cobicistat

Ability to drive, dasabuvir [2] ---> SmPC of [2] of EMA

Patients should be informed that fatigue has been reported during treatment with dasabuvir in combination with ombitasvir/paritaprevir/ritonavir and ribavirin

Ability to drive, dasatinib [2] ---> SmPC of [2] of EMA

Patients should be advised that they may experience adverse reactions such as dizziness or blurred vision during treatment with dasatinib.

Ability to drive, daunorubicin [2] ---> SmPC of [2] of eMC

Daunorubicin hydrochloride causes episodes of nausea and vomiting, which sometimes can lead to impairment of the ability to drive or use machines.

Ability to drive, daunorubicin/cytarabine [2] ---> SmPC of [2] of EMA

Fatigue and dizziness have been reported with the use of Vyxeos. Therefore, caution is recommended when driving or operating machines.

Ability to drive, decitabine [2] ---> SmPC of [2] of EMA

Patients should be advised that they may experience undesirable effects such as anaemia during treatment.

Ability to drive, deferasirox [2] ---> SmPC of [2] of EMA

Patients experiencing the uncommon adverse reaction of dizziness should exercise caution when driving or operating machinery

Ability to drive, deferoxamine

Dizziness and other central nervous system disorders or vision and hearing disorders may occur

Ability to drive, defibrotide [2] ---> SmPC of [2] of EMA

Patients would not be expected to drive or operate machinery due to the nature of the underlying disease.

Ability to drive, degarelix [2] ---> SmPC of [2] of EMA

Fatigue and dizziness are common adverse reactions that might influence the ability to drive and use machines.

Ability to drive, delafloxacin [2] ---> SmPC of [2] of EMA

Some adverse drug reactions (e.g. dizziness, headache, visual disorders) may impair the patient's ability to concentrate and react

Ability to drive, delamanid [2] ---> SmPC of [2] of EMA

Patients should be advised not to drive or use machines if they experience any adverse reaction with a potential impact on the ability to perform these activities (e.g. headache and tremor are very common).

Ability to drive, delapril

As with other antihypertensives, the ability to drive and use machines may be reduced

Ability to drive, demeclocycline [2] ---> SmPC of [2] of eMC

Headache, dizziness, visual disturbances may occur

Ability to drive, dengue tetravalent vaccine [2] ---> SmPC of [2] of EMA

Dengvaxia has minor influence on the ability to drive and use machines.

Ability to drive, Dengue tetravalent vaccine [2] ---> SmPC of [2] of EMA

Qdenga has minor influence on the ability to drive and use machines.

Ability to drive, desflurane

Patients should be advised that the ability to perform tasks such as driving or operation of machinery may be impaired after general anaesthesia, and it is advisable to avoid such tasks for a period of 24 hours.

Ability to drive, desloratadine [2] ---> SmPC of [2] of EMA

Patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.

Ability to drive, desloratadine/pseudoephedrine [2] ---> SmPC of [2] of EMA

It is recommended that patients are advised not to engage in activities requiring mental alertness, until they have established their own response to the medicinal product.

Ability to drive, dexamethasone [2] ---> SmPC of [2] of EMA

Patients may experience temporarily reduced vision after receiving dexamethasone by intravitreal injection

Ability to drive, dexchlorpheniramine

Somnolence may occur

Ability to drive, dexibuprofen [2] ---> SmPC of [2] of eMC

During treatment with dexibuprofen the patient's reaction capacity may be reduced when dizziness or fatigue appear as side effects.

Ability to drive, dexketoprofen [2] ---> SmPC of [2] of eMC

Dizziness or drowsiness may occur

Ability to drive, dexmedetomidine [2] ---> SmPC of [2] of EMA

Patients should be advised to refrain from driving or other hazardous tasks for a suitable period of time after receiving Dexdor for procedural sedation.

Ability to drive, dexrazoxane [2] ---> SmPC of [2] of EMA

Dizziness, somnolence and syncope have been reported in a few patients included in Savene studies TT01 and TT02. Dexrazoxane has minor influence on the ability to drive and use machines.

Ability to drive, dextromethorphan [2] ---> SmPC of [2] of eMC

Unlikely to produce an effect.

Ability to drive, dextromethorphan/quinidine [2] ---> SmPC of [2] of EMA

Patients should be warned about the potential for CNS-related effects like somnolence, dizziness and syncope or impaired vision

Ability to drive, dextropropoxyphene

The opioid analgesic may cause somnolence, decreased psychic alertness and vertigo

Ability to drive, diamorphine [2] ---> SmPC of [2] of eMC

Diamorphine causes drowsiness and mental clouding.

Ability to drive, diazepam [2] ---> SmPC of [2] of eMC

Sedation, amnesia, impaired concentration, and impaired muscular function may adversely affect the ability to drive or use machines.

Ability to drive, diclofenac [2] ---> SmPC of [2] of eMC

Undesirable effects such as dizziness, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs. If affected, patients should not drive or operate machinery.

Ability to drive, difelikefalin [2] ---> SmPC of [2] of EMA

Somnolence and/or dizziness have been reported in patients receiving difelikefalin. Dizziness occurred within the first 9 weeks of treatment and was generally transient.

Ability to drive, digoxin [2] ---> SmPC of [2] of eMC

Since central nervous system and visual disturbances have been reported, patients should exercise caution before driving, using machinery or participating in dangerous activities.

Ability to drive, dihydrocodeine [2] ---> SmPC of [2] of eMC

Dihydrocodeine produces sedation and may also cause changes in vision, including blurred or double vision. If affected, patients should not drive or operate machinery.

Ability to drive, dihydroergotamine

Changes in the ability to react

Ability to drive, dihydroergotoxine

Decreased ability to react

Ability to drive, diltiazem [2] ---> SmPC of [2] of eMC

On the basis of reported adverse drug reactions, i.e. dizziness (common), malaise (common), the ability to drive and use machines could be altered. However, no studies have been performed.

Ability to drive, dimenhydrinate

Somnolence, memory disorders and decreased concentration ability may occur

Ability to drive, dimethindene

Decreased ability to react may occur

Ability to drive, dinutuximab [2] ---> SmPC of [2] of EMA

Unituxin has major influence on the ability to drive and use machines.

Ability to drive, diphenhydramine [2] ---> SmPC of [2] of eMC

Diphenhydramine has a major influence on the ability to drive and use machines. It is a hypnotic and will produce drowsiness or sedation soon after the dose has been taken.

Ability to drive, dipivefrine

Mydriasis may occur

Ability to drive, dipotassium clorazepate

The sedative effect affects the ability to drive or use machines

Ability to drive, disopyramide [2] ---> SmPC of [2] of eMC

Some adverse reactions may impair the patient's ability to concentrate and react, and hence the ability to drive or operate machinery.

Ability to drive, distigmine

Miosis and abnormal accommodation may occur

Ability to drive, disulfiram [2] ---> SmPC of [2] of eMC

Disulfiram may cause side effects such as drowsiness or fatigue.

Ability to drive, dolutegravir [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness has been reported during treatment with dolutegravir.

Ability to drive, dolutegravir/abacavir/lamivudine [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness has been reported during treatment with dolutegravir.

Ability to drive, dolutegravir/lamivudine [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness and somnolence has been reported during treatment with dolutegravir.

Ability to drive, dolutegravir/rilpivirine [2] ---> SmPC of [2] of EMA

Patients should be informed that fatigue, dizziness and somnolence have been reported during treatment with the components of Juluca.

Ability to drive, donepezil [2] ---> SmPC of [2] of eMC

Donepezil can induce fatigue, dizziness and muscle cramps

Ability to drive, doravirine [2] ---> SmPC of [2] of EMA

Patients should be informed that fatigue, dizziness, and somnolence have been reported during treatment with doravirine (see section 4.8). This should be considered when assessing a patient's ability to drive or operate machinery.

Ability to drive, doravirine/lamivudine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA

Patients should be informed that fatigue, dizziness, and somnolence have been reported during treatment with Delstrigo. This should be considered when assessing a patient's ability to drive or operate machinery.

Ability to drive, dorzolamide/timolol [2] ---> SmPC of [2] of eMC

Possible side effects such as blurred vision may affect some patients' ability to drive and/or operate machinery.

Ability to drive, doxazosin [2] ---> SmPC of [2] of eMC

The ability to engage in activities such as operating machinery or operating a motor vehicle may be impaired, especially when initiating therapy.

Ability to drive, doxepin [2] ---> SmPC of [2] of eMC

Since drowsiness may occur, patients should be warned of the possibility and cautioned against driving a car or operating machinery while taking this drug.

Ability to drive, doxorubicin pegylated liposomal [2] ---> SmPC of [2] of EMA

In clinical studies to date, dizziness and somnolence were associated infrequently (< 5%) with the administration of doxorubicin pegylated liposomal. Patients who suffer from these effects must avoid driving and operating machinery.

Ability to drive, doxorubicine [2] ---> SmPC of [2] of eMC

Due to the frequent occurrence of nausea and vomiting, driving cars and operation of machinery should be discouraged.

Ability to drive, doxylamine

Decreased ability to react may occur

Ability to drive, dronedarone [2] ---> SmPC of [2] of EMA

Ability to drive and use machines may be affected by adverse reactions such as fatigue.

Ability to drive, droperidol [2] ---> SmPC of [2] of eMC

Patients should not drive or operate a machine for 24 hours after droperidol administration.

Ability to drive, dulaglutide [2] ---> SmPC of [2] of EMA

Patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines

Ability to drive, duloxetine [2] ---> SmPC of [2] of EMA

Duloxetine may be associated with sedation and dizziness.

Ability to drive, efavirenz [2] ---> SmPC of [2] of EMA

Efavirenz may cause dizziness, impaired concentration, and/or somnolence.

Ability to drive, elbasvir/grazoprevir [2] ---> SmPC of [2] of EMA

Patients should be informed that fatigue has been reported during treatment with ZEPATIER

Ability to drive, elcatonin

Injectable elcatonin may cause transient dizziness

Ability to drive, eletriptan [2] ---> SmPC of [2] of eMC

Migraine or treatment with eletriptan may cause drowsiness or dizziness in some patients.

Ability to drive, elosulfase alfa [2] ---> SmPC of [2] of EMA

Dizziness was reported during elosulfase alfa infusions; if dizziness occurs after the infusion, the ability to drive and use machines may be affected.

Ability to drive, elotuzumab [2] ---> SmPC of [2] of EMA

Patients experiencing infusion reactions should be advised not to drive and use machines until symptoms abate.

Ability to drive, eltrombopag [2] ---> SmPC of [2] of EMA

The clinical status of the patient and the adverse reaction profile of eltrombopag, including dizziness and lack of alertness, should be borne in mind when considering the patient's ability to perform tasks that require judgment, motor and cognitive skil

Ability to drive, eluxadoline [2] ---> SmPC of [2] of EMA

Due to events of somnolence and sedation observed in clinical studies, caution should be exercised

Ability to drive, elvitegravir [2] ---> SmPC of [2] of EMA

No studies on the effects of elvitegravir on the ability to drive and use machines have been performed.

Ability to drive, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness has been reported during treatment with Genvoya.

Ability to drive, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness has been reported during treatment with Stribild.

Ability to drive, emedastine [2] ---> SmPC of [2] of EMA

As with any ocular medication, if transient blurred vision or other visual disturbance occurs at instillation, the patient should wait until the vision clears before driving or using machinery.

Ability to drive, empagliflozin [2] ---> SmPC of [2] of EMA

Patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines

Ability to drive, empagliflozin/linagliptin [2] ---> SmPC of [2] of EMA

Patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines

Ability to drive, empagliflozin/metformin [2] ---> SmPC of [2] of EMA

Patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines

Ability to drive, emtricitabine [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness has been reported during treatment with emtricitabine.

Ability to drive, emtricitabine/rilpivirine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA

Patients should be informed that fatigue, dizziness and somnolence have been reported during treatment with the components of Odefsey

Ability to drive, emtricitabine/rilpivirine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA

Dizziness and somnolence have been reported during treatment

Ability to drive, emtricitabine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness has been reported during treatment with Descovy.

Ability to drive, emtricitabine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA

Individuals should be informed that dizziness has been reported during treatment with both emtricitabine and tenofovir disoproxil fumarate.

Ability to drive, enalapril [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.

Ability to drive, enalapril/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur

Ability to drive, encorafenib [2] ---> SmPC of [2] of EMA

Patients should be advised not to drive or use machines if they experience visual disturbances or any other adverse reactions that may affect their ability to drive and use machines

Ability to drive, enfuvirtide [2] ---> SmPC of [2] of EMA

There is no evidence that enfuvirtide may alter the patient's ability to drive and use machines, however, the adverse event profile of enfuvirtide should be taken into account

Ability to drive, entacapone [2] ---> SmPC of [2] of EMA

Entacapone may, together with levodopa, cause dizziness and symptomatic orthostatism.

Ability to drive, entecavir [2] ---> SmPC of [2] of EMA

Dizziness, fatigue and somnolence are common side effects which may impair the ability to drive and use machines.

Ability to drive, entrectinib [2] ---> SmPC of [2] of EMA

Patients should be instructed not to drive or use machines until the symptoms resolve, if they experience cognitive adverse reactions, syncope, blurred vision, or dizziness, during treatment with Rozlytrek

Ability to drive, enzalutamide [2] ---> SmPC of [2] of EMA

Enzalutamide may have a moderate influence on the ability to drive and use machines as psychiatric and neurologic events including seizure have been reported

Ability to drive, epinephrine [2] ---> SmPC of [2] of eMC

Not applicable; this preparation is intended for use only in emergencies.

Ability to drive, epirubicin [2] ---> SmPC of [2] of eMC

Epirubicin may cause episodes of nausea and vomiting, which can temporarily lead to an impairment of the ability to drive or operate machines.

Ability to drive, eplerenone [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that dizziness may occur during treatment.

Ability to drive, eprosartan [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines, it should be taken into account, that occasionally dizziness or weariness may occur during treatment of hypertension.

Ability to drive, eptacog beta [2] ---> SmPC of [2] of EMA

The active substance eptacog beta (activated) may have a minor influence on the ability to drive and use machines. Dizziness may occur following administration of the active substance eptacog beta (see section 4.8).

Ability to drive, eptifibatide [2] ---> SmPC of [2] of EMA

Eptifibatide is intended for use only in hospitalised patients

Ability to drive, eravacycline [2] ---> SmPC of [2] of EMA

Eravacycline may have a minor influence on the ability to drive and use machines. Dizziness may occur following administration of eravacycline

Ability to drive, ergot derivatives

Dizziness and feelings of anxiety may occur

Ability to drive, ergotamine

Changes in the ability to react

Ability to drive, eribulin [2] ---> SmPC of [2] of EMA

HALAVEN may cause adverse reactions such as tiredness and dizziness which may lead to minor or moderate influence on the ability to drive or use machines.

Ability to drive, erlotinib [2] ---> SmPC of [2] of EMA

No studies on the effects on the ability to drive and use machines have been performed; however erlotinib is not associated with impairment of mental ability.

Ability to drive, ertapenem [2] ---> SmPC of [2] of EMA

Dizziness and somnolence may occur

Ability to drive, escitalopram [2] ---> SmPC of [2] of eMC

Any psychoactive medicinal product may impair judgment or skills.

Ability to drive, esketamine

Esketamine may decrease the ability to react

Ability to drive, esketamine [2] ---> SmPC of [2] of EMA

In clinical studies, Spravato has been reported to cause somnolence, sedation, dissociative symptoms, perception disturbances, dizziness, vertigo and anxiety

Ability to drive, eslicarbazepine [2] ---> SmPC of [2] of EMA

Some patients might experience dizziness, somnolence or visual disorders, particularly on initiation of treatment.

Ability to drive, esomeprazole [2] ---> SmPC of [2] of EMA

Esomeprazole has a minor influence on the ability to drive or use machines. Adverse reactions such as dizziness and visual disturbances are uncommon. If affected, patients should not drive or use machines.

Ability to drive, etelcalcetide [2] ---> SmPC of [2] of EMA

Certain potential manifestations of hypocalcaemia may affect the ability to drive and use machines

Ability to drive, ethambutol

Patients who suffer from visual impairment during treatment with ethambutol should not drive or operate machinery.

Ability to drive, ethosuximide [2] ---> SmPC of [2] of eMC

Patients should be cautioned that ethosuximide may cause drowsiness and if this occurs should avoid driving or operating machinery.

Ability to drive, ethyl loflazepate

The sedative effect affects the ability to drive or use machines

Ability to drive, etilefrine

Dizziness may occur

Ability to drive, etomidate [2] ---> SmPC of [2] of eMC

It is not recommended to use potentially dangerous machinery or to drive a car during the first 24 hours after administration.

Ability to drive, etoposide [2] ---> SmPC of [2] of eMC

None.

Ability to drive, etoricoxib [2] ---> SmPC of [2] of eMC

Patients who experience dizziness, vertigo or somnolence while taking etoricoxib should refrain from driving or operating machinery.

Ability to drive, etranacogene dezaparvovec [2] ---> SmPC of [2] of EMA

Because of potential adverse reactions such as temporary dizziness, fatigue, and headache that have occurred shortly after etranacogene dezaparvovec administration, patients should be advised to use caution when driving and operating machinery

Ability to drive, etravirine [2] ---> SmPC of [2] of EMA

Somnolence and vertigo may occur

Ability to drive, everolimus [2] ---> SmPC of [2] of EMA

Patients should be advised to be cautious when driving or using machines if they experience fatigue during treatment

Ability to drive, ex vivo expanded autologous human corneal epithelial cells [2] ---> SmPC of [2] of EMA

Following treatment with Holoclar, driving and using machines must be limited and patients should follow the advice of their treating physician.

Ability to drive, exemestane [2] ---> SmPC of [2] of eMC

Drowsiness, somnolence, asthenia and dizziness have been reported with the use of the drug.

Ability to drive, exenatide [2] ---> SmPC of [2] of EMA

When prolonged-release exenatide is used in combination with a sulphonylurea, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines.

Ability to drive, ezetimibe [2] ---> SmPC of [2] of eMC

Dizziness has been reported.

Ability to drive, ezetimibe/atorvastatin [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines, it should be taken into account that dizziness has been reported.

Ability to drive, ezetimibe/simvastatine [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines, it should be taken into account that dizziness has been reported.

Ability to drive, famciclovir [2] ---> SmPC of [2] of eMC

Patients who experience dizziness, somnolence, confusion or other central nervous system disturbances while taking Famciclovir Tablets should refrain from driving or operating machinery.

Ability to drive, famotidine

Dizziness and headache may occur

Ability to drive, fampridine [2] ---> SmPC of [2] of EMA

Fampyra has moderate influence on the ability to drive and use machines because Fampyra can cause dizziness.

Ability to drive, faricimab [2] ---> SmPC of [2] of EMA

Temporary visual disturbances may occur following the intravitreal injection and the associated eye examination. Patients should not drive or use machines until visual function has recovered sufficiently.

Ability to drive, febuxostat [2] ---> SmPC of [2] of EMA

Patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that ADENURIC does not adversely affect performance.

Ability to drive, fedratinib [2] ---> SmPC of [2] of EMA

Patients who experience dizziness after taking Inrebic should refrain from driving or using machines.

Ability to drive, felbamate

Dizziness or drowsiness may occur

Ability to drive, felodipine [2] ---> SmPC of [2] of eMC

Patients should know how they react to felodipine before they drive or use machines because occasionally dizziness or fatigue may occur.

Ability to drive, felodipine/metoprolol

Patients should be aware of how they might be affected by felodipine/metoprolol before driving or using machines.

Ability to drive, felodipine/ramipril [2] ---> SmPC of [2] of eMC

Some symptoms of reduction in blood pressure such as dizziness may be accompanied by an impairment of the ability to concentrate and react.

Ability to drive, fenfluramine [2] ---> SmPC of [2] of EMA

Patients should be advised not to drive or operate machinery until they have gained sufficient experience to gauge whether it adversely affects their abilities

Ability to drive, fenofibrate/simvastatin [2] ---> SmPC of [2] of EMA

Dizziness has been reported rarely in post-marketing experience with simvastatin.

Ability to drive, fenoterol

Central nervous or cardiovascular adverse effects may occur

Ability to drive, fentanyl [2] ---> SmPC of [2] of EMA

Patients should be advised not to drive or operate machinery if they experience somnolence, dizziness, or visual disturbance while taking Effentora and not to drive or operate machinery until they know how they react.

Ability to drive, ferumoxytol [2] ---> SmPC of [2] of EMA

In the case of symptoms of dizziness, confusion or light headedness following the administration of Rienso, patients should not drive or use machinery until the symptoms have ceased.

Ability to drive, fesoterodine [2] ---> SmPC of [2] of EMA

TOVIAZ has minor influence on the ability to drive and use machines. Caution should be exercised when driving or using machines due to possible occurrence of side effects such as blurred vision, dizziness, and somnolence

Ability to drive, fexofenadine [2] ---> SmPC of [2] of eMC

It is advisable to check the individual response before driving or performing complicated tasks.

Ability to drive, filgotinib [2] ---> SmPC of [2] of EMA

Filgotinib has no or negligible influence on the ability to drive and use machines. However, patients should be advised that dizziness has been reported during treatment with Jyseleca

Ability to drive, filgrastim [2] ---> SmPC of [2] of EMA

Grastofil has minor or moderate influence on the ability to drive and use machines. Caution is advised when driving a car or operating machinery.

Ability to drive, fingolimod [2] ---> SmPC of [2] of EMA

Dizziness or drowsiness may occasionally occur when initiating therapy with Gilenya.

Ability to drive, flavoxate [2] ---> SmPC of [2] of eMC

In the event of drowsiness, blurred vision and vertigo, the patient should not operate a motor vehicle or machinery.

Ability to drive, flecainide [2] ---> SmPC of [2] of eMC

Driving ability, operation of machinery and work without a secure fit may be affected by adverse reactions such as dizziness and visual disturbances, if present.

Ability to drive, fluconazole [2] ---> SmPC of [2] of eMC

Patients should be warned about the potential for dizziness or seizures while taking fluconazole and should be advised not to drive or operate machines if any of these symptoms occur.

Ability to drive, fludarabine [2] ---> SmPC of [2] of eMC

Fludarabine may reduce the ability to drive and use machines, since e.g. fatigue, weakness, visual disturbances, confusion, agitation and seizures have been observed.

Ability to drive, flumazenil [2] ---> SmPC of [2] of eMC

Patients who have received flumazenil to reverse the effects of benzodiazepine sedation should be warned not to drive, to operate machinery or to engage in any other physically or mentally demanding activity for at least 24 hours

Ability to drive, flunarizine

Somnolence may occur

Ability to drive, flunitrazepam

Sedation, amnesia, decreased concentration ability and muscle function alteration may occur

Ability to drive, fluorescein [2] ---> SmPC of [2] of eMC

If mydriasis is necessary for the examination with fluorescence angiography visual acuity is influenced and thus affects the ability to react in traffic or use machinery.

Ability to drive, fluorouracil [2] ---> SmPC of [2] of eMC

Fluorouracil may induce side effects such as nausea and vomiting. It can also produce adverse event on nervous system and visual changes which could interfere driving or the usage of heavy machinery.

Ability to drive, fluoxetine [2] ---> SmPC of [2] of eMC

Although fluoxetine has been shown not to affect psychomotor performance in healthy volunteers, any psychoactive drug may impair judgement or skills.

Ability to drive, flupentixol [2] ---> SmPC of [2] of eMC

Alertness may be impaired, especially at the start of treatment, or following the consumption of alcohol. Patients should not drive if they have blurred vision.

Ability to drive, fluphenazine [2] ---> SmPC of [2] of eMC

The use of this drug may impair the mental and physical abilities required for driving a car or operating heavy machinery.

Ability to drive, flurazepam [2] ---> SmPC of [2] of eMC

Patients should be advised that, flurazepam might modify patients' performance at skilled tasks (driving, operating machinery, etc.) to a varying degree depending upon dosage, administration, and sleep pattern and individual susceptibility

Ability to drive, fluspirilene

Changes in the ability to react

Ability to drive, flutamide

Fatigue, dizziness and confusion may occur

Ability to drive, flutemetamol (18 F) [2] ---> SmPC of [2] of EMA

VIZAMYL may cause transient dizziness and vertigo.

Ability to drive, fluvoxamine [2] ---> SmPC of [2] of eMC

Somnolence has been reported during treatment with fluvoxamine. Therefore, caution is recommended until the individual response to the drug has been determined.

Ability to drive, fomepizole

Decreased ability to react

Ability to drive, fomivirsen [2] ---> SmPC of [2] of EMA

Temporary blurred vision may occur

Ability to drive, formoterol [2] ---> SmPC of [2] of eMC

Patients experiencing dizziness or other similar side effects should be advised to refrain from driving or using machines.

Ability to drive, formoterol/glycopyrronium/budesonide [2] ---> SmPC of [2] of EMA

Dizziness is an uncommon side effect which should be taken into account when driving or using machines.

Ability to drive, fosamprenavir [2] ---> SmPC of [2] of EMA

The adverse reaction profile of Telzir should be borne in mind when considering the patient's ability to drive or operate machinery

Ability to drive, fosaprepitant [2] ---> SmPC of [2] of EMA

Dizziness and fatigue may occur following administration of IVEMEND

Ability to drive, foscarnet [2] ---> SmPC of [2] of eMC

Due to the disease itself and possible undesirable effects of foscarnet (such as dizziness and convulsions), the ability to drive and use machines can be impaired.

Ability to drive, fosfomycin

Dizziness may occur

Ability to drive, fosinopril [2] ---> SmPC of [2] of eMC

It can cause adverse effects such as dizziness, vertigo or hypotension. Patients should make sure they are not affected before driving or operating machinery.

Ability to drive, fosphenytoin [2] ---> SmPC of [2] of eMC

Treatment with fosphenytoin may cause central nervous system adverse effects such as dizziness and drowsiness

Ability to drive, fostamatinib [2] ---> SmPC of [2] of EMA

Fostamatinib is not expected to influence the ability to drive or to use machines. The patient should avoid driving cars or using machines if feeling dizzy.

Ability to drive, fostemsavir [2] ---> SmPC of [2] of EMA

The clinical status of the patient and the adverse reaction profile of fostemsavir should be borne in mind when considering the patient's ability to drive or operate machinery.

Ability to drive, fotemustine

Fotemustine may affect ability to drive and use machines

Ability to drive, frovatriptan [2] ---> SmPC of [2] of eMC

Migraine or treatment with frovatriptan may cause somnolence.

Ability to drive, fulvestrant [2] ---> SmPC of [2] of EMA

Since asthenia has been reported very commonly with Faslodex, caution should be observed by those patients who experience this adverse reaction when driving or operating machinery.

Ability to drive, furosemide [2] ---> SmPC of [2] of eMC

Reduced mental alertness may impair ability to drive or operate dangerous machinery.

Ability to drive, gabapentin [2] ---> SmPC of [2] of eMC

Gabapentin acts on the central nervous system and may cause drowsiness, dizziness or other related symptoms.

Ability to drive, gadopentetic acid

Vomiting or hypotension may occur

Ability to drive, gadoteric acid

Vomiting may occur

Ability to drive, gadoversetamide [2] ---> SmPC of [2] of EMA

Ambulant patients while driving vehicles or operating machinery should take into account that acute dizziness may uncommonly occur

Ability to drive, galantamine [2] ---> SmPC of [2] of eMC

Galantamine has minor or moderate influence on the ability to drive and use machines. Symptoms include dizziness and somnolence, especially during the first weeks after initiation of treatment.

Ability to drive, galcanezumab [2] ---> SmPC of [2] of EMA

Galcanezumab may have a minor influence on the ability to drive and use machines. Vertigo may occur following the administration of galcanezumab

Ability to drive, ganciclovir

Seizures, sedation, dizziness and/or confusional states may occur

Ability to drive, gefitinib [2] ---> SmPC of [2] of EMA

During treatment with gefitinib, asthenia has been reported. Therefore, patients who experience this symptom should be cautious when driving or using machines.

Ability to drive, gemcitabine [2] ---> SmPC of [2] of eMC

Patients should be cautioned against driving or operating machinery until it is established that they do not become somnolent.

Ability to drive, gemfibrozil [2] ---> SmPC of [2] of eMC

In isolated cases dizziness and visual disturbances can occur which may negatively influence driving.

Ability to drive, gemtuzumab ozogamicin [2] ---> SmPC of [2] of EMA

Patients should be advised they may experience fatigue, dizziness and headache during treatment with MYLOTARG. Therefore, caution should be exercised when driving or operating machines.

Ability to drive, gilteritinib [2] ---> SmPC of [2] of EMA

Gilteritinib has minor influence on the ability to drive and use machines. Dizziness has been reported in patients taking Xospata and should be considered when assessing a patient's ability to drive or use machines

Ability to drive, glasdegib [2] ---> SmPC of [2] of EMA

Patients experiencing fatigue or other symptoms (e.g., muscle cramps, pain, nausea) affecting the ability to react normally while taking Daurismo should exercise caution when driving or operating machines.

Ability to drive, glibenclamide [2] ---> SmPC of [2] of EMA

AMGLIDIA has moderate influence on the ability to drive and use machines since glibenclamide may increase the risk of hypoglycaemia.

Ability to drive, gliclazide [2] ---> SmPC of [2] of eMC

Patients should be informed that their concentration may be affected if their diabetes is not satisfactorily controlled, especially at the beginning of treatment

Ability to drive, glimepiride [2] ---> SmPC of [2] of eMC

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment.

Ability to drive, glipizide [2] ---> SmPC of [2] of eMC

Patients should be aware of the symptoms of hypoglycaemia and be careful about driving and the use of machinery,

Ability to drive, gliquidone

Hypoglycemia may impair the reaction and concentration ability

Ability to drive, glucagon [2] ---> SmPC of [2] of EMA

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia which may persist for a brief period after receiving treatment.

Ability to drive, glucagon [2] ---> SmPC of [2] of eMC

After diagnostic procedures hypoglycaemia has been reported infrequently.

Ability to drive, glucosamine

Dizziness or drowsiness may occur

Ability to drive, glycerol phenylbutyrate [2] ---> SmPC of [2] of EMA

RAVICTI may have major influence on the ability to drive and use machines given that treatment with glycerol phenylbutyrate may cause dizziness or headaches. Patients should not drive or use machines whilst experiencing these side effects.

Ability to drive, glycerol trinitrate

Nitroglycerin can cause postural hypotension and dizziness

Ability to drive, glycerol trinitrate [2] ---> SmPC of [2] of eMC

As glyceryl trinitrate can cause dizziness patients should make sure they are not affected before driving or operating machinery.

Ability to drive, golimumab [2] ---> SmPC of [2] of EMA

Dizziness may occur following administration

Ability to drive, guanethidine [2] ---> SmPC of [2] of eMC

Dizziness, blurred vision or drowsiness may occur

Ability to drive, guanfacin [2] ---> SmPC of [2] of EMA

Intuniv can cause dizziness and somnolence.

Ability to drive, halogenated anaesthetics

The out-patients should not drive or use any tools or machines within the 24 hours after the anesthesia

Ability to drive, haloperidol [2] ---> SmPC of [2] of eMC

Some degree of sedation or impairment of alertness may occur, particularly with higher doses and at the start of treatment, and may be potentiated by alcohol or other CNS depressants.

Ability to drive, hemp extract

Dizziness and somnolence may occur

Ability to drive, hepatitis B vaccine [2] ---> SmPC of [2] of EMA

HEPLISAV B may have a moderate influence on the ability to drive and use machine. Some of the effects mentioned under Section 4.8 "Undesirable Effects" (e.g., malaise) may affect the ability to drive or operate machinery.

Ability to drive, histamine

Hypotension, dizziness, light-headedness and blurred vision may occur

Ability to drive, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

Ceplene can cause hypotension and may result in dizziness, light-headedness and blurred vision.

Ability to drive, human alpha1-proteinase inhibitor [2] ---> SmPC of [2] of EMA

Dizziness may occur following the administration of Respreeza. Therefore, Respreeza may have a minor influence on the ability to drive and use machines.

Ability to drive, human insulin [2] ---> SmPC of [2] of EMA

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia.

Ability to drive, human normal immunoglobulin [2] ---> SmPC of [2] of EMA

The ability to drive and operate machines may be impaired by some adverse reactions associated with KIOVIG.

Ability to drive, human papillomavirus 9-valent vaccine (recombinant, adsorbed) [2] ---> SmPC of [2] of EMA

There were no serious adverse experiences reported in infants who were breast-feeding during the vaccination period.

Ability to drive, hydralazine

Dizziness or fatigue may occasionally occur in patients taking antihypertensive therapy

Ability to drive, hydrochlorothiazide

Hydrochlorothiazid may cause dizziness, headache and vertigo

Ability to drive, hydrocodone

Decreased ability to react

Ability to drive, hydrocortisone [2] ---> SmPC of [2] of EMA

Plenadren has minor influence on the ability to drive and use machines. Fatigue and episodes of short-lasting vertigo have been reported. Untreated and poorly replaced adrenal insufficiency may affect the ability to drive and use machines.

Ability to drive, hydromorphone [2] ---> SmPC of [2] of eMC

Hydromorphone may cause drowsiness and patients should not drive or operate machinery if affected.

Ability to drive, hydroquinidine

Depending on the individual patient's response the ability to drive a vehicle or to use machines may be impaired.

Ability to drive, hydroxycarbamide [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness has been reported from literature, but not commonly. Patients should be advised not to drive or operate machines, if dizziness is experienced while taking Siklos.

Ability to drive, hydroxychloroquine [2] ---> SmPC of [2] of eMC

Impaired visual accommodation soon after the start of treatment has been reported and patients should be warned regarding driving or operating machinery.

Ability to drive, hydroxyzine [2] ---> SmPC of [2] of eMC

Patients should be warned that hydroxyzine may impair their ability to perform activities requiring mental alertness or physical co-ordination such as operating machinery or driving a vehicle.

Ability to drive, ibalizumab [2] ---> SmPC of [2] of EMA

Dizziness, nausea, fatigue and headache have been reported during treatment with ibalizumab. Patients experiencing these symptoms should be advised to use caution when driving or using machines until symptoms abate.

Ability to drive, ibritumomab tiuxetan [2] ---> SmPC of [2] of EMA

Dizziness may occur

Ability to drive, ibrutinib [2] ---> SmPC of [2] of EMA

Fatigue, dizziness and asthenia have been reported in some patients taking IMBRUVICA and should be considered when assessing a patient's ability to drive or operate machines.

Ability to drive, ibuprofen [2] ---> SmPC of [2] of eMC

None expected at recommended doses and duration of therapy.

Ability to drive, icatibant [2] ---> SmPC of [2] of EMA

Fatigue, lethargy, tiredness, somnolence, and dizziness have been reported following the use of Firazyr. These symptoms may occur as a result of an attack of HAE.

Ability to drive, idarubicin [2] ---> SmPC of [2] of eMC

The effect of idarubicin on the ability to drive or use machinery has not been systematically evaluated.

Ability to drive, idecabtagene vicleucel [2] ---> SmPC of [2] of EMA

Patients receiving Abecma should refrain from driving or operating heavy or potentially dangerous machines for at least 8 weeks after Abecma infusion or until resolution of neurologic adverse reactions.

Ability to drive, ifosfamide

Ifosfamide can lead to impairment of the ability to drive a vehicle or to operate machinery, directly by inducing encephalopathy and indirectly by inducing nausea and vomiting

Ability to drive, iloprost [2] ---> SmPC of [2] of EMA

Ventavis has major influence on the ability to drive and use machines for patients experiencing hypotensive symptoms such as dizziness.

Ability to drive, imatinib [2] ---> SmPC of [2] of EMA

Patients should be advised that they may experience undesirable effects such as dizziness, blurred vision or somnolence during treatment with imatinib. Therefore, caution should be recommended when driving a car or operating machinery.

Ability to drive, imidapril [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.

Ability to drive, imipenem/cilastatin [2] ---> SmPC of [2] of eMC

There are some side effects (such as hallucination, dizziness, somnolence, and vertigo) associated with this product that may affect some patients' ability to drive or operate machinery

Ability to drive, imipenem/cilastatin/relebactam [2] ---> SmPC of [2] of EMA

CNS adverse reactions, such as seizures, confusional states, and myoclonic activity, have been reported during treatment with imipenem/cilastatin, components of Recarbrio, especially when recommended dosages of imipenem were exceeded

Ability to drive, imipramine [2] ---> SmPC of [2] of eMC

Blurred vision, drowsiness and other CNS symptoms may occur.

Ability to drive, immunocyanin

Decreased ability to react

Ability to drive, indacaterol/glycopyrronium [2] ---> SmPC of [2] of EMA

This medicinal product has no or negligible influence on the ability to drive and use machines. However, the occurrence of dizziness may influence the ability to drive and use machines

Ability to drive, indapamide [2] ---> SmPC of [2] of eMC

In individual cases the hypotensive effect may impact on a patient´s ability to drive and operate machinery, especially at the start of treatment or when another antihypertensive agent is added.

Ability to drive, indinavir [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness and blurred vision have been reported during treatment with indinavir.

Ability to drive, indometacin [2] ---> SmPC of [2] of eMC

Patients should be warned that they may experience dizziness, drowsiness, visual disturbances or headaches and if they do, should not drive or undertake activities requiring alertness.

Ability to drive, infliximab [2] ---> SmPC of [2] of EMA

Dizziness may occur following administration of Inflectra

Ability to drive, influenza vaccine

Dizziness and paraesthesia may occur

Ability to drive, inotuzumab ozogamicin [2] ---> SmPC of [2] of EMA

Patients may experience fatigue during treatment with BESPONSA (see section 4.8). Therefore, caution is recommended when driving or operating machines.

Ability to drive, insulin aspart [2] ---> SmPC of [2] of EMA

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia.

Ability to drive, insulin degludec [2] ---> SmPC of [2] of EMA

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia.

Ability to drive, insulin degludec/insulin aspart [2] ---> SmPC of [2] of EMA

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia.

Ability to drive, insulin degludec/liraglutide [2] ---> SmPC of [2] of EMA

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia.

Ability to drive, insulin detemir [2] ---> SmPC of [2] of EMA

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia.

Ability to drive, insulin glargin [2] ---> SmPC of [2] of EMA

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment.

Ability to drive, insulin glargine/lixisenatide [2] ---> SmPC of [2] of EMA

the patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment.

Ability to drive, insulin glulisin [2] ---> SmPC of [2] of EMA

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment.

Ability to drive, insulin lispro [2] ---> SmPC of [2] of EMA

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia.

Ability to drive, insulin [2] ---> SmPC of [2] of EMA

Take precautions to avoid hypoglycaemia whilst driving or operating machinery

Ability to drive, interferon alfa-2a

Interferon alfa-2a may impair the ability to react

Ability to drive, interferon alfa-2b [2] ---> SmPC of [2] of EMA

Patients are to be advised that they may develop fatigue, somnolence, or confusion during treatment with IntronA, and therefore it is recommended that they avoid driving or operating machinery.

Ability to drive, interferon beta-1a [2] ---> SmPC of [2] of EMA

Central nervous system-related adverse events associated with the use of interferon beta (e.g. dizziness) might influence the patient's ability to drive or use machines

Ability to drive, interferon beta-1b [2] ---> SmPC of [2] of EMA

Central nervous system-related adverse events may influence the ability to drive and use machines in susceptible patients.

Ability to drive, interferon gamma-1b

Fatigue, seizures, states of confusion, desorientation or hallucinations may occur

Ability to drive, iodinated contrast media

The iodinated contrast agents may cause late reactions

Ability to drive, iodixanol

It is not recommended to drive and use machines during the first 24 hours after an intrathecal exploration

Ability to drive, iohexol

It is not recommended to drive and use machines during the first 24 hours after an intrathecal exploration

Ability to drive, iomeprol [2] ---> SmPC of [2] of eMC

There is no known effect on the ability to drive and operate machines. After intrathecal administration, it is recommended that the patient should wait 24 hours before driving or operating machinery.

Ability to drive, ipilimumab [2] ---> SmPC of [2] of EMA

Because of potential adverse reactions such as fatigue, patients should be advised to use caution when driving or operating machinery until they are certain that ipilimumab does not adversely affect them.

Ability to drive, ipratropium

Dizziness, accommodation disorder, mydriasis and blurred vision may occur

Ability to drive, irbesartan [2] ---> SmPC of [2] of EMA

When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.

Ability to drive, irbesartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Dizziness or weariness may occur

Ability to drive, irinotecan [2] ---> SmPC of [2] of EMA

ONIVYDE has moderate influence on the ability to drive and use machines. During treatment patients should observe caution when driving or using machines.

Ability to drive, isavuconazole [2] ---> SmPC of [2] of EMA

Isavuconazole has a moderate potential to influence the ability to drive and use machines. Patients should avoid driving or operating machinery if symptoms of confusional state, somnolence, syncope, and/or dizziness are experienced.

Ability to drive, isocarboxazid [2] ---> SmPC of [2] of eMC

Like all medicaments of this type, Isocarboxazid may modify patients' reactions

Ability to drive, isoflurane [2] ---> SmPC of [2] of eMC

Patients should be advised that performance of activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, may be impaired for 2-4 days after anaesthesia with isoflurane.

Ability to drive, isoniazid [2] ---> SmPC of [2] of eMC

Patients should be warned of the possibility of convulsions, psychosis and optic neuritis

Ability to drive, isosorbide dinitrate [2] ---> SmPC of [2] of eMC

Headaches, tiredness, dizziness. These may affect the ability to drive and operate machinery.

Ability to drive, isosorbide mononitrate [2] ---> SmPC of [2] of eMC

Isosorbide mononitrate may, owing to side effects (e.g. dizziness), affect the ability to drive and use machines to a slight or moderate extent. This action is potentiated by intake of alcohol.

Ability to drive, isothipendyl

Somnolence may occur

Ability to drive, isotretinoin [2] ---> SmPC of [2] of eMC

A number of cases of decreased night vision have occurred during isotretinoin therapy and in rare instances have persisted after therapy

Ability to drive, isradipine [2] ---> SmPC of [2] of eMC

As with other calcium channel blockers, syncope, dizziness, hypotension, visual disturbances and blurred vision are known adverse reactions associated with the use of isradipine.

Ability to drive, itraconazol [2] ---> SmPC of [2] of eMC

Possibility of adverse reactions such as dizziness, visual disturbances and hearing loss may occur

Ability to drive, ivabradine [2] ---> SmPC of [2] of EMA

In post-marketing experience, cases of impaired driving ability due to visual symptoms have been reported. Ivabradine may cause transient luminous phenomena consisting mainly of phosphenes

Ability to drive, ivacaftor [2] ---> SmPC of [2] of EMA

Ivacaftor may cause dizziness and, therefore, patients experiencing dizziness should be advised not to drive or use machines until symptoms abate.

Ability to drive, ivacaftor/tezacaftor/elexacaftor [2] ---> SmPC of [2] of EMA

Patients experiencing dizziness should be advised not to drive or use machines until symptoms abate.

Ability to drive, ivosidenib [2] ---> SmPC of [2] of EMA

Fatigue and dizziness have been reported in some patients taking ivosidenib (see section 4.8) and should be considered when assessing a patient's ability to drive or operate machines.

Ability to drive, ixazomib [2] ---> SmPC of [2] of EMA

NINLARO has minor influence on the ability to drive or use machines. Fatigue and dizziness have been observed in clinical trials. Patients should be advised not to drive or operate machines if they experience any of these symptoms.

Ability to drive, ketamine [2] ---> SmPC of [2] of eMC

Patients should be cautioned that driving a car, operating hazardous machinery or engaging in hazardous activities should not be undertaken for 24 hours or more after anaesthesia.

Ability to drive, ketoconazole [2] ---> SmPC of [2] of EMA

Patients should be warned about the potential for dizziness and somnolence and should be advised not to drive or operate machines if any of these symptoms occur.

Ability to drive, ketoprofen [2] ---> SmPC of [2] of eMC

Patients should be warned about the potential for somnolence, dizziness or convulsions, drowsiness, fatigue and visual disturbances and be advised not to drive or operate machinery if these symptoms occur.

Ability to drive, ketorolac [2] ---> SmPC of [2] of eMC

Some patients may experience dizziness, drowsiness, fatigue, visual disturbances, headaches, vertigo, insomnia or depression.

Ability to drive, ketotifen [2] ---> SmPC of [2] of eMC

During the first few days of treatment with ketotifen reactions may be impaired. Patients should be warned not to take charge of vehicles or machinery until the effect of ketotifen treatment on the individual is known.

Ability to drive, labetalol

Decreased ability to react

Ability to drive, lacidipine [2] ---> SmPC of [2] of eMC

Lacidipine may cause dizziness.

Ability to drive, lacosamide [2] ---> SmPC of [2] of EMA

It is unknown whether lacosamide is excreted in human breast milk. Animal studies have shown excretion of lacosamide in breast milk. For precautionary measures, breast-feeding should be discontinued during treatment with lacosamide.

Ability to drive, lamivudine [2] ---> SmPC of [2] of EMA

Patients should be informed that malaise and fatigue have been reported during treatment with lamivudine.

Ability to drive, lamivudine/raltegravir [2] ---> SmPC of [2] of EMA

Dizziness has been reported in some patients during treatment with regimens containing raltegravir, which may influence some patients' ability to drive and use machines

Ability to drive, lamotrigine [2] ---> SmPC of [2] of eMC

Patients should see how lamotrigine therapy affects them before driving or operating machinery.

Ability to drive, lanreotide [2] ---> SmPC of [2] of eMC

Dizziness has been reported

Ability to drive, lansoprazole [2] ---> SmPC of [2] of eMC

Adverse drug reactions such as dizziness, vertigo, visual disturbances and somnolence may occur. Under these conditions the ability to react may be decreased.

Ability to drive, lanthanum carbonate [2] ---> SmPC of [2] of eMC

Lanthanum carbonate may induce dizziness and vertigo, which may impair the ability to drive and use machinery.

Ability to drive, lapatinib [2] ---> SmPC of [2] of EMA

The clinical status of the patient and the adverse event profile of lapatinib should be borne in mind when considering the patient's ability to perform tasks that require judgement, motor or cognitive skills.

Ability to drive, laropiprant [2] ---> SmPC of [2] of EMA

Dizziness may occur

Ability to drive, laropiprant/nicotinic acid [2] ---> SmPC of [2] of EMA

Dizziness has been reported

Ability to drive, larotrectinib [2] ---> SmPC of [2] of EMA

Dizziness and fatigue have been reported in patients receiving larotrectinib, mostly Grade 1 and 2 during the first 3 months of treatment. This may influence the ability to drive and use machines during this time period.

Ability to drive, latanoprost [2] ---> SmPC of [2] of eMC

In common with other eye preparations, instillation of eye drops may cause transient blurring of vision.

Ability to drive, latanoprost/netarsudil [2] ---> SmPC of [2] of EMA

If transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machines.

Ability to drive, latanoprost/timolol [2] ---> SmPC of [2] of eMC

Instillation of eye drops may cause transient blurring of vision.

Ability to drive, ledipasvir/sofosbuvir [2] ---> SmPC of [2] of EMA

Patients should be advised that fatigue was more common in patients treated with ledipasvir/sofosbuvir compared to placebo.

Ability to drive, leflunomide [2] ---> SmPC of [2] of EMA

In the case of side effects such as dizziness the patient's ability to concentrate and to react properly may be impaired. In such cases patients should refrain from driving cars and using machines.

Ability to drive, lenalidomide [2] ---> SmPC of [2] of EMA

Fatigue, dizziness, somnolence, vertigo and blurred vision have been reported with the use of lenalidomide. Therefore, caution is recommended when driving or operating machines.

Ability to drive, lenvatinib [2] ---> SmPC of [2] of EMA

Lenvatinib has a minor influence on the ability to drive and use machines, due to undesirable effects such as fatigue and dizziness. Patients who experience these symptoms should use caution when driving or operating machines.

Ability to drive, lercanidipine [2] ---> SmPC of [2] of eMC

Caution should be exercised because dizziness, asthenia, fatigue and rarely somnolence may occur.

Ability to drive, letermovir [2] ---> SmPC of [2] of EMA

Fatigue and vertigo have been reported in some patients during treatment with PREVYMIS, which may influence a patient's ability to drive and use machines

Ability to drive, letrozol [2] ---> SmPC of [2] of eMC

Fatigue and dizziness have been observed with the use of letrozole

Ability to drive, leuprorelin [2] ---> SmPC of [2] of EMA

The administration of this medicinal product can cause fatigue, dizziness and visual disturbances (see sections 4.8). Patients should be advised not to drive or operate machinery if these adverse reactions occur.

Ability to drive, levacetylmethadol [2] ---> SmPC of [2] of EMA

Administration of levacetylmethadol may cause drowsiness or euphoria.

Ability to drive, levetiracetam [2] ---> SmPC of [2] of EMA

Somnolence or other central nervous system related symptoms may occur

Ability to drive, levobunolol [2] ---> SmPC of [2] of eMC

Levobunolol may cause transient blurring of vision, fatigue and/or drowsiness which may impair the ability to drive or operate machines

Ability to drive, levobupivacaine [2] ---> SmPC of [2] of eMC

Patients should be warned not to drive or operate machinery until all the effects of the anaesthesia and the immediate effects of surgery are passed.

Ability to drive, levocabastine

Vision blurred may occur

Ability to drive, levocetirizine [2] ---> SmPC of [2] of eMC

Some patients could experience somnolence, fatigue and asthenia under therapy

Ability to drive, levodopa [2] ---> SmPC of [2] of EMA

Certain side effects such as sleepiness and dizziness, that have been reported with other forms of levodopa medicinal products, may affect some patients' ability to drive or use machines.

Ability to drive, levodopa/benserazide [2] ---> SmPC of [2] of eMC

Patients presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death

Ability to drive, levodopa/carbidopa [2] ---> SmPC of [2] of EMA

Certain side effects such as sleepiness and dizziness that have been reported with this modified-release levodopa/carbidopa capsule medicinal product may affect some patients' ability to drive or operate machinery.

Ability to drive, levodopa/carbidopa/entacapone [2] ---> SmPC of [2] of EMA

Levodopa, carbidopa and entacapone together may cause dizziness and symptomatic orthostatism.

Ability to drive, levodropropizine

Somnolence may occur

Ability to drive, levofloxacin [2] ---> SmPC of [2] of EMA

Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient's ability to concentrate and react

Ability to drive, levomepromazine [2] ---> SmPC of [2] of eMC

Levomepromazine can cause drowsiness, disorientation, confusion or excessive hypotension, which may affect the patient's ability to drive or operate machinery.

Ability to drive, levomethadone

Changes in the ability to react

Ability to drive, levosulpiride

Levosulpiride acts on the central nervous system and may cause somnolence, dizziness, visual disturbances and decreased ability to react

Ability to drive, linagliptin [2] ---> SmPC of [2] of EMA

Patients should be alerted to the risk of hypoglycaemia especially when combined with sulphonylurea and/or insulin.

Ability to drive, linagliptin/metformin [2] ---> SmPC of [2] of EMA

Patients should be alerted to the risk of hypoglycaemia when Jentadueto is used in combination with other antidiabetic medicinal products known to cause hypoglycaemia (e.g. sulphonylureas).

Ability to drive, linezolid [2] ---> SmPC of [2] of eMC

Patients should be warned about the potential for dizziness or symptoms of visual impairment whilst receiving linezolid

Ability to drive, liposomal bupivacaine [2] ---> SmPC of [2] of EMA

Patients should be informed in advance that bupivacaine liposomal dispersion can cause temporary loss of sensation or motor function.

Ability to drive, liposome-encapsulated doxorubicin-citrate complex [2] ---> SmPC of [2] of EMA

Myocet has been reported to cause dizziness. Patients who suffer from this should avoid driving and operating machinery.

Ability to drive, liraglutide [2] ---> SmPC of [2] of EMA

Patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines, in particular when Victoza is used in combination with a sulfonylurea or a basal insulin.

Ability to drive, lisdexamfetamine [2] ---> SmPC of [2] of eMC

Lisdexamfetamine can cause dizziness, drowsiness and visual disturbances including difficulties with accommodation, diplopia and blurred vision.

Ability to drive, lisinopril [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or tiredness may occur.

Ability to drive, lisinopril/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or tiredness may occur.

Ability to drive, lisocabtagene maraleucel [2] ---> SmPC of [2] of EMA

Due to the potential for neurologic events, including altered mental status or seizures with Breyanzi, patients should refrain from driving or operating heavy or potentially dangerous machines for at least 8 weeks after Breyanzi infusion.

Ability to drive, lisuride

Lisuride may cause somnolence and a sudden fall in blood pressure

Ability to drive, lithium carbonate [2] ---> SmPC of [2] of eMC

Lithium may slow reaction time, and considering the adverse reactions profile of lithium, patients should be warned of the possible hazards when driving or operating machinery

Ability to drive, lithium [2] ---> SmPC of [2] of eMC

Lithium may slow reaction time, and considering the adverse reactions profile of lithium, patients should be warned of the possible hazards when driving or operating machinery

Ability to drive, lixisenatide [2] ---> SmPC of [2] of EMA

When used in combination with a sulphonylurea or a basal insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines.

Ability to drive, local anaesthetics

Transient decrease of the ability to react

Ability to drive, lodoxamide [2] ---> SmPC of [2] of eMC

As with any topical ophthalmic medicinal product, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines.

Ability to drive, lofepramine [2] ---> SmPC of [2] of eMC

Ability to drive a car and operate machinery may be affected.

Ability to drive, lomefloxacin

The table may decrease the ability to react. The instillation of eye drops may cause a transient blurring of vision

Ability to drive, lomustine [2] ---> SmPC of [2] of eMC

Lomustine can impair the ability to drive and use machines, e.g. because of nausea and vomiting

Ability to drive, lonafarnib [2] ---> SmPC of [2] of EMA

Lonafarnib has a minor influence on the ability to drive and use machines. Fatigue may occur following the administration of lonafarnib

Ability to drive, loncastuximab tesirine [2] ---> SmPC of [2] of EMA

Fatigue has been reported in patients taking loncastuximab tesirine and this should be taken into account when driving or using machines.

Ability to drive, loperamide [2] ---> SmPC of [2] of eMC

Loss of consciousness, depressed level of consciousness, tiredness, dizziness, or drowsiness may occur when diarrhoea is treated with loperamide.

Ability to drive, lopinavir

Nausea may occur

Ability to drive, lopinavir/ritonavir [2] ---> SmPC of [2] of EMA

Patients should be informed that nausea has been reported during treatment with Kaletra.

Ability to drive, loprazolam [2] ---> SmPC of [2] of eMC

Attention should be drawn to the risk of drowsiness, sedation, amnesia, impaired concentration and muscular weakness

Ability to drive, loratadine [2] ---> SmPC of [2] of eMC

Very rarely some people experience drowsiness, which may affect their ability to drive or use machines.

Ability to drive, lorazepam [2] ---> SmPC of [2] of eMC

Patients should be advised that sedation, amnesia, impaired concentration, dizziness, blurred vision and impaired muscular function may occur

Ability to drive, lorlatinib [2] ---> SmPC of [2] of EMA

Lorlatinib has moderate influence on the ability to drive and use machines. Caution should be exercised when driving or operating machines as patients may experience CNS effects

Ability to drive, lormetazepam

Sedation, amnesia, dizziness and impaired muscular function may adversely affect the ability to drive or use machines.

Ability to drive, lornoxicam

Dizziness and/or somnolence may occur

Ability to drive, losartan [2] ---> SmPC of [2] of eMC

It must be borne in mind that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy

Ability to drive, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

It must be borne in mind that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy, in particular during initiation of treatment or when the dose is increased.

Ability to drive, loteprednol [2] ---> SmPC of [2] of eMC

If there are any transient effects on vision, the patient should be advised to wait until these subside before driving or operating machinery.

Ability to drive, lovastatine

Dizziness has been reported rarely in post-marketing experience with lovastatin

Ability to drive, loxapine [2] ---> SmPC of [2] of EMA

Sedation/somnolence, fatigue, or dizziness may occur. ADASUVE has major influence on the ability to drive and use machines.

Ability to drive, lumacaftor/ivacaftor [2] ---> SmPC of [2] of EMA

Ivacaftor, which is one of the active components of Orkambi, has a minor influence on the ability to drive or use machines. Ivacaftor may cause dizziness

Ability to drive, lumiracoxib

Dizziness, vertigo or somnolence may occur

Ability to drive, lurasidone [2] ---> SmPC of [2] of EMA

Patients should be cautioned about operating hazardous machines, including motor vehicles, until they are reasonably certain that lurasidone does not affect them adversely

Ability to drive, luspatercept [2] ---> SmPC of [2] of EMA

The ability to react when performing these tasks may be impaired due to risks of fatigue, vertigo, dizziness or syncope

Ability to drive, macimorelin [2] ---> SmPC of [2] of EMA

In case a patient should be reporting dizziness as side effect, the patient should be instructed to neither drive nor use machines.

Ability to drive, macitentan [2] ---> SmPC of [2] of EMA

The clinical status of the patient and the adverse reaction profile of macitentan (such as headache, hypotension) should be kept in mind when considering the patient's ability to drive and use machines.

Ability to drive, manidipine

Dizziness may occur

Ability to drive, maprotiline

Dizziness, blurred vision, drowsiness and other CNS symptoms may occur

Ability to drive, maraviroc [2] ---> SmPC of [2] of EMA

Maraviroc may cause dizziness.

Ability to drive, mecasermin [2] ---> SmPC of [2] of EMA

Hypoglycaemia is a very common adverse reaction. In case of a hypoglycaemic episode INCRELEX may have major influence on the ability to drive or use machines.

Ability to drive, medazepam

The sedative effect affects the ability to drive or use machines

Ability to drive, mefloquine [2] ---> SmPC of [2] of eMC

Dizziness, vertigo or a loss of balance, or other disorders of the central or peripheral nervous system and psychiatric disorders have been reported during and following the use of mefloquine.

Ability to drive, melatonin [2] ---> SmPC of [2] of EMA

Melatonin may cause drowsiness

Ability to drive, meloxicam

Dizziness, drowsiness, fatigue and visual disturbances may occur

Ability to drive, melperone

The ability to drive and use machines may be reduced

Ability to drive, melphalan [2] ---> SmPC of [2] of EMA

It is likely that certain adverse reactions of melphalan, like nausea and vomiting, could affect this ability. This medicinal product also contains alcohol, which is likely to affect children and adolescents

Ability to drive, memantin [2] ---> SmPC of [2] of EMA

Memantine has minor to moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care.

Ability to drive, meningococcal vaccine

Dizziness may occur

Ability to drive, mephenytoin

Decreased ability to react

Ability to drive, mepivacaine

Transient decrease of the ability to react

Ability to drive, meprobamate [2] ---> SmPC of [2] of eMC

This product may cause drowsiness or dizziness which may adversely affect the ability to drive or operate machinery.

Ability to drive, meptazinol [2] ---> SmPC of [2] of eMC

Since dizziness and occasionally drowsiness have been reported, patients should be cautioned against driving or operating machinery until it is established that they do not become dizzy or drowsy whilst taking meptazinol.

Ability to drive, mequitazine

Somnolence may occur

Ability to drive, mercaptamine [2] ---> SmPC of [2] of EMA

Somnolence may occur

Ability to drive, meropenem/vaborbactam [2] ---> SmPC of [2] of EMA

Vabomere has moderate influence on the ability to drive and use machines. Seizures have been reported during treatment with meropenem alone, especially in patients treated with anticonvulsants

Ability to drive, mesna

Nauseas and vomiting may occur

Ability to drive, mesuximide

It may alter the capacity to react

Ability to drive, metamizole

Possible decreased ability to react

Ability to drive, metformin [2] ---> SmPC of [2] of eMC

Patients should be alerted to the risk of hypoglycaemia when metformin is used in combination with other antidiabetic agents (sulphonylureas, insulin, repaglinide).

Ability to drive, metformin/saxagliptin/dapagliflozin [2] ---> SmPC of [2] of EMA

When driving or using machines, it should be taken into account that dizziness has been reported in studies with saxagliptin.

Ability to drive, methadone [2] ---> SmPC of [2] of eMC

Methadone may produce drowsiness and patients should be advised not to drive or operate machinery if affected.

Ability to drive, methantheline

This medicinal product can affect the visual acuity

Ability to drive, methocarbamol

Drowsiness may occur

Ability to drive, methotrexate [2] ---> SmPC of [2] of EMA

Central nervous system (CNS) symptoms, such as fatigue and confusion, can occur during treatment.

Ability to drive, methoxsalen

Cardiovascular instability may occur

Ability to drive, methyldopa [2] ---> SmPC of [2] of eMC

Methyldopa may cause sedation, usually transient, during the initial period of therapy or whenever the dose is increased. If affected, patients should not carry out activities where alertness is necessary

Ability to drive, methylergometrine

Vertigo and seizures may occur

Ability to drive, methylnaltrexone [2] ---> SmPC of [2] of EMA

Dizziness may occur and this may have an effect on the ability to drive and use machines

Ability to drive, methylphenidate [2] ---> SmPC of [2] of eMC

Methylphenidate may cause dizziness, drowsiness and visual disturbances including difficulties with accommodations, diplopia and blurred vision.

Ability to drive, methylprednisolone [2] ---> SmPC of [2] of eMC

There is no evidence to suggest that methylprednisolone tablets may affect the ability to drive and use machines. No deleterious effects of corticosteroids on driving or operating machinery ability is expected

Ability to drive, methylthioninium [2] ---> SmPC of [2] of EMA

Methylthioninium chloride has moderate influence on the ability to drive and use machines. Indeed, driving can be affected due to confusional state, dizziness and possibly eye disturbances.

Ability to drive, methysergide [2] ---> SmPC of [2] of eMC

Patients should be warned of the potential hazards of driving or operating machinery if they experience side effects such as dizziness, drowsiness or disturbances in vision.

Ability to drive, metildigoxin

Dizziness and fatigue may occur

Ability to drive, metipranolol

The ability to react can be influenced

Ability to drive, metoclopramide [2] ---> SmPC of [2] of eMC

This medicine may cause drowsiness, dizziness, dyskinesia and dystonias which could affect the vision and also interfere with the ability to drive and operate machinery.

Ability to drive, metoprolol

It may alter the capacity to react

Ability to drive, metreleptin [2] ---> SmPC of [2] of EMA

Myalepta has minor influence on the ability to drive and use machines due to fatigue and dizziness.

Ability to drive, metronidazole [2] ---> SmPC of [2] of eMC

Patients should be warned about the potential for drowsiness, dizziness, confusion, hallucinations, convulsions or transient visual disorders, and advised not to drive or operate machinery if these symptoms occur.

Ability to drive, metyrapone [2] ---> SmPC of [2] of eMC

Patients should be warned of the potential hazards of driving or operating machinery if they experience side effects such as dizziness and sedation.

Ability to drive, mexiletine [2] ---> SmPC of [2] of EMA

Mexiletine may have minor influence on the ability to drive and use machines. Fatigue, confusion, blurred vision may occur following administration of mexiletine

Ability to drive, mianserin

Mianserin may affect the psychomotor performance during the first days of treatment

Ability to drive, micafungin [2] ---> SmPC of [2] of EMA

Adverse reactions may occur, which may influence the ability to drive and use machines

Ability to drive, midazolam [2] ---> SmPC of [2] of EMA

Sedation, amnesia, impaired attention and impaired muscular function may occur

Ability to drive, midecamycin

Vomiting and headaches may occur

Ability to drive, midodrine

Dizziness or headlessness may occur

Ability to drive, midostaurin [2] ---> SmPC of [2] of EMA

Dizziness and vertigo have been reported in patients taking Rydapt and should be considered when assessing a patient's ability to drive or use machines.

Ability to drive, mifamurtide [2] ---> SmPC of [2] of EMA

Dizziness, vertigo, fatigue and blurred vision may occur

Ability to drive, miglitol

Take precautions to avoid hypoglycaemia whilst driving or operating machinery

Ability to drive, miglustat [2] ---> SmPC of [2] of EMA

Dizziness has been reported as a common adverse reaction

Ability to drive, milnacipran

Changes in the ability to react

Ability to drive, miltefosine

Nausea may occur

Ability to drive, minocycline [2] ---> SmPC of [2] of eMC

Lightheadedness, visual disturbances, dizziness, tinnitus and vertigo have occurred

Ability to drive, minoxidil [2] ---> SmPC of [2] of eMC

The ability to drive or operate machinery may be influenced by the individual response to treatment, particularly at the start of therapy.

Ability to drive, mirtazapine [2] ---> SmPC of [2] of eMC

Mirtazapine may impair concentration and alertness (particularly in the initial phase of treatment).

Ability to drive, misoprostol [2] ---> SmPC of [2] of eMC

Misoprostol can cause dizziness.

Ability to drive, mitapivat [2] ---> SmPC of [2] of EMA

Patients should be advised to be cautious when driving or using machines in case they experience insomnia during treatment with Pyrukynd

Ability to drive, mitotane [2] ---> SmPC of [2] of EMA

Lysodren has a major influence on the ability to drive and use machines. Ambulatory patients should be warned not to drive or use machines.

Ability to drive, mitoxantrone

Drowsiness and confusion may occur

Ability to drive, mivacurium [2] ---> SmPC of [2] of eMC

Mivacurium will always be used in combination with a general anaesthetic and therefore the usual precautions relating to performance of tasks following general anaesthesia apply.

Ability to drive, mizolastine [2] ---> SmPC of [2] of eMC

It is advisable to check the individual response before driving or performing complicated tasks.

Ability to drive, moclobemide [2] ---> SmPC of [2] of eMC

Impairment of performance in activities requiring complete mental alertness (e.g. driving a motor vehicle) is generally not to be expected. The individual reaction should however be monitored during early treatment.

Ability to drive, modafinil [2] ---> SmPC of [2] of eMC

Patients with abnormal levels of sleepiness who take modafinil should be advised that their level of wakefulness may not return to normal.

Ability to drive, moexipril [2] ---> SmPC of [2] of eMC

The intake of ACE inhibitors may - as any antihypertensive therapy - induce hypotension with subsequent impairment of reactivity.

Ability to drive, mogamulizumab [2] ---> SmPC of [2] of EMA

Mogamulizumab has minor influence on the ability to drive and use machines. Fatigue may occur following administration of mogamulizumab

Ability to drive, molsidomine

Dizziness may occur

Ability to drive, montelukast [2] ---> SmPC of [2] of eMC

In very rare cases, individuals have reported drowsiness or dizziness.

Ability to drive, morphine [2] ---> SmPC of [2] of eMC

Morphine may modify the patient's reactions to a varying extent depending on the dosage and susceptibility. If affected, patients should not drive or operate machinery.

Ability to drive, mosunetuzumab [2] ---> SmPC of [2] of EMA

Lunsumio has minor influence on the ability to drive and use machines. Patients who experience events that impair consciousness should be evaluated

Ability to drive, moxifloxacin [2] ---> SmPC of [2] of eMC

Fluoroquinolones including moxifloxacin may result in an impairment of the patient's ability to drive or operate machinery due to CNS reactions or acute and short lasting loss of consciousness (syncope)

Ability to drive, moxonidine [2] ---> SmPC of [2] of eMC

Somnolence and dizziness have been reported. This should be borne in mind when performing these tasks.

Ability to drive, mytomicin [2] ---> SmPC of [2] of eMC

Generalized weakness and lethargy have been reported on rare occasions. If affected, patients should be advised not to drive or operate machinery.

Ability to drive, nabilone [2] ---> SmPC of [2] of eMC

Nabilone may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as operating machinery or driving a car

Ability to drive, nabumetone [2] ---> SmPC of [2] of eMC

Undesirable effects such as dizziness, drowsiness, confusion, fatigue and visual disturbances are possible after taking NSAIDs.

Ability to drive, nadolol [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or fatigue may occur.

Ability to drive, nalbuphine

The injection solution has a great influence on ability to react

Ability to drive, nalmefene [2] ---> SmPC of [2] of EMA

Nausea, dizziness, insomnia, and headache may occur

Ability to drive, naloxone

It is recommended not to make physical and psychical efforts for at least 24 hours after treatment

Ability to drive, naltrexone [2] ---> SmPC of [2] of eMC

Naltrexone may impair the mental and/or physical abilities required for performance of potentially hazardous tasks such as driving a car or operating machinery.

Ability to drive, naltrexone/bupropion [2] ---> SmPC of [2] of EMA

Patients who experience dizziness, somnolence, loss of consciousness or seizure should be advised to avoid driving or operating machines until these adverse effects have resolved.

Ability to drive, naphazoline [2] ---> SmPC of [2] of eMC

Do not drive or operate machinery if vision is blurred.

Ability to drive, naproxen [2] ---> SmPC of [2] of eMC

Undesirable effects such as dizziness, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs.

Ability to drive, naproxen/esomeprazole [2] ---> SmPC of [2] of eMC

Based on that some of the adverse effects (e.g. dizziness) reported following the use naproxen/omeprazole may reduce the ability to react.

Ability to drive, naratriptan [2] ---> SmPC of [2] of eMC

Caution is recommended in patients performing skilled tasks (e.g. driving or operating machinery) as drowsiness may occur as a result of migraine.

Ability to drive, narcotine

Noscapine can impair alertness and reactivity

Ability to drive, natalizumab [2] ---> SmPC of [2] of EMA

Given that dizziness has been commonly reported, patients who experience this adverse reaction should be advised not to drive or use machines until it has resolved.

Ability to drive, nateglinide [2] ---> SmPC of [2] of EMA

Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.

Ability to drive, nebivolol [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that dizziness and fatigue may occasionally occur.

Ability to drive, necitumumab [2] ---> SmPC of [2] of EMA

If patients experience treatment-related symptoms affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides.

Ability to drive, nelarabine [2] ---> SmPC of [2] of EMA

Patients treated with nelarabine are potentially at risk of suffering from somnolence during and for several days after treatment.

Ability to drive, neostigmine [2] ---> SmPC of [2] of eMC

Not known.

Ability to drive, nepafenac [2] ---> SmPC of [2] of EMA

Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines.

Ability to drive, neratinib [2] ---> SmPC of [2] of EMA

Fatigue, dizziness, dehydration, and syncope have been reported as adverse reactions with neratinib.

Ability to drive, netarsudil [2] ---> SmPC of [2] of EMA

If transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machines.

Ability to drive, netupitant/palonosetron [2] ---> SmPC of [2] of EMA

Akynzeo has moderate influence on the ability to drive and use machines. Since it may induce dizziness, somnolence or fatigue, patients should be cautioned not to drive or use machines if such symptoms occur.

Ability to drive, nevirapine [2] ---> SmPC of [2] of EMA

Patients should be advised that they may experience adverse reactions such as fatigue during treatment

Ability to drive, nicardipine [2] ---> SmPC of [2] of eMC

Caution should be exercised because the hypotensive effects of this drug may cause dizziness.

Ability to drive, nicergoline

Weakness, dizziness or fatigue may occur

Ability to drive, niclosamide

Changes in the ability to react

Ability to drive, nicomorphine

Decreased attention and ability to concentrate and react

Ability to drive, nicorandil [2] ---> SmPC of [2] of eMC

Blood pressure-lowering effects of nicorandil can reduce the ability to drive or to use machines.

Ability to drive, nifedipine [2] ---> SmPC of [2] of eMC

Reactions to nifedipine may vary in intensity in patients

Ability to drive, nilotinib [2] ---> SmPC of [2] of EMA

It is recommended that patients experiencing dizziness, fatigue, visual impairment or other undesirable effects with a potential impact on the ability to drive or use machines safely should refrain from these activities as long as the undesirable effects

Ability to drive, nilvadipine

Dizziness may occur

Ability to drive, nimesulide

Somnolence, dizziness or fatigue may occur

Ability to drive, nimodipine [2] ---> SmPC of [2] of eMC

In theory, the possibility of the occurrence of the side-effect dizziness may impair the patient's ability to drive or operate machinery.

Ability to drive, nintedanib [2] ---> SmPC of [2] of EMA

Patients should be advised to be cautious when driving or using machines during treatment with Vargatef.

Ability to drive, niraparib [2] ---> SmPC of [2] of EMA

Patients who take Zejula may experience asthenia, fatigue and dizziness. Patients who experience these symptoms should observe caution when driving or using machines.

Ability to drive, nirmatrelvir/ritonavir [2] ---> SmPC of [2] of EMA

Paxlovid is expected to have no influence on the ability to drive and use machines.

Ability to drive, nirsevimab [2] ---> SmPC of [2] of EMA

Not applicable.

Ability to drive, nisoldipine

Nisoldipine may alter the capacity to react

Ability to drive, nitisinone [2] ---> SmPC of [2] of EMA

Adverse reactions involving the eyes can affect the vision.

Ability to drive, nitrazepam [2] ---> SmPC of [2] of eMC

Sedation, amnesia, impaired concentration and impaired muscle function may adversely affect the ability to drive or use machinery.

Ability to drive, nitrendipine

Nitrendipine may impair your ability to drive or operate machines.

Ability to drive, nitrofurantoin [2] ---> SmPC of [2] of eMC

Nitrofurantoin may cause dizziness and drowsiness.

Ability to drive, nitroglycerine [2] ---> SmPC of [2] of eMC

As glyceryl trinitrate can cause dizziness patients should make sure they are not affected before driving or operating machinery.

Ability to drive, nitroprussiate

Disorientation, dizziness and blurred vision may occur

Ability to drive, nivolumab [2] ---> SmPC of [2] of EMA

Because of potential adverse reactions such as fatigue, patients should be advised to use caution when driving or operating machinery until they are certain that nivolumab does not adversely affect them.

Ability to drive, nivolumab/relatlimab [2] ---> SmPC of [2] of EMA

Because of potential adverse reactions such as fatigue and dizziness (see section 4.8), patients should be advised to use caution when driving or operating machines until they are certain that Opdualag does not adversely affect them.

Ability to drive, norfloxacin

Norfloxacin may alter the capacity to react

Ability to drive, norpseudoephedrine

Changes in the ability to react

Ability to drive, nortriptyline [2] ---> SmPC of [2] of eMC

Nortriptyline may impair the mental and/or physical abilities required for the performance of hazardous tasks, such as operating machinery or driving a car; therefore the patient should be warned accordingly.

Ability to drive, noscapine

Noscapine can impair alertness and reactivity

Ability to drive, obiltoxaximab [2] ---> SmPC of [2] of EMA

Obiltoxaximab may have a minor influence on the ability to drive and use machines since headache, dizziness, fatigue and vomiting may occur following administration of Obiltoxaximab SFL

Ability to drive, obinutuzumab [2] ---> SmPC of [2] of EMA

Infusion-related reactions are very common during the first infusion of obinutuzumab, and patients experiencing infusion related symptoms should be advised not to drive or use machines until symptoms abate.

Ability to drive, ocriplasmin [2] ---> SmPC of [2] of EMA

The intravitreal injection of JETREA may be followed by temporary visual disturbances

Ability to drive, ofatumumab [2] ---> SmPC of [2] of EMA

The clinical status of the patient and the ADR profile of ofatumumab should be borne in mind when considering the patient's ability to perform tasks that require judgement, motor or cognitive skills

Ability to drive, ofloxacin [2] ---> SmPC of [2] of eMC

There have been occasional reports of somnolence, impairment of skills, dizziness and visual disturbances

Ability to drive, olanzapine [2] ---> SmPC of [2] of EMA

Olanzapine may cause somnolence and dizziness

Ability to drive, olaparib [2] ---> SmPC of [2] of EMA

During treatment with Lynparza, asthenia, fatigue, and dizziness have been reported and those patients who experience these symptoms should observe caution when driving or using machines.

Ability to drive, olaratumab [2] ---> SmPC of [2] of EMA

Due to frequent occurrence of fatigue, patients should be advised to use caution when driving or operating machinery.

Ability to drive, olipudase alfa [2] ---> SmPC of [2] of EMA

Because hypotension has been reported in clinical studies, Xenpozyme may have minor influence on the ability to drive and use machines (see section 4.8).

Ability to drive, olmesartan medoxomil [2] ---> SmPC of [2] of eMC

Dizziness or fatigue may occasionally occur in patients taking antihypertensive therapy, which may impair the ability to react.

Ability to drive, olmesartan medoxomil/amlodipine [2] ---> SmPC of [2] of eMC

Dizziness, headache, nausea or fatigue may occasionally occur in patients taking antihypertensive therapy, which may impair the ability to react. Caution is recommended especially at the start of treatment.

Ability to drive, olmesartan [2] ---> SmPC of [2] of eMC

Dizziness or fatigue may occasionally occur in patients taking antihypertensive therapy, which may impair the ability to react.

Ability to drive, olopatadine [2] ---> SmPC of [2] of EMA

As with any eye drop, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines.

Ability to drive, ombitasvir/paritaprevir/ritonavir [2] ---> SmPC of [2] of EMA

Patients should be informed that fatigue has been reported during treatment with Viekirax in combination with dasabuvir and ribavirin

Ability to drive, omeprazole [2] ---> SmPC of [2] of eMC

If side effects such as dizziness and light headedness are experienced the ability to drive and use machines may be affected

Ability to drive, opicapone [2] ---> SmPC of [2] of EMA

Opicapone in association with levodopa may have major influence on the ability to drive and use machines. Opicapone may, together with levodopa, cause dizziness, symptomatic orthostatism and somnolence.

Ability to drive, opioid analgesics ---> SmPC of [dextropropoxyphene] of eMC

The opioid analgesic may cause somnolence, decreased psychic alertness and vertigo

Ability to drive, opipramol

Drowsiness or fatigue may occur

Ability to drive, oral antidiabetics

Take precautions to avoid hypoglycaemia whilst driving or operating machinery

Ability to drive, orciprenaline

Orciprenaline may cause nervousness, feeling of restlessness and dizziness

Ability to drive, oritavancin [2] ---> SmPC of [2] of EMA

Dizziness may occur and this may have an effect on driving and use of machines

Ability to drive, ornidazole

Somnolence, dizziness, tremor, rigidity and seizures may occur

Ability to drive, orphenadrine [2] ---> SmPC of [2] of eMC

Patients must be advised to exercise caution while driving or operating machinery or whilst carrying out other skilled tasks.

Ability to drive, osilodrostat [2] ---> SmPC of [2] of EMA

Patients should be warned about the potential for dizziness and fatigue (see section 4.8) and should be advised not to drive or use machines if these symptoms occur.

Ability to drive, oxaliplatin [2] ---> SmPC of [2] of eMC

Oxaliplatin treatment resulting in an increased risk of dizziness, nausea and vomiting, and other neurologic symptoms that affect gait and balance

Ability to drive, oxazepam [2] ---> SmPC of [2] of eMC

Sedation, amnesia and impaired muscular function may adversely affect the ability to drive or use machines.

Ability to drive, oxcarbazepine [2] ---> SmPC of [2] of eMC

The use of oxcarbazepine has been associated with adverse reactions such as dizziness or somnolence

Ability to drive, oxomemazine

Decreased ability to react

Ability to drive, oxprenolol [2] ---> SmPC of [2] of eMC

Patients receiving oxprenolol should be warned that dizziness, fatigue or visual disturbances may occur

Ability to drive, oxybuprocaine

It may alter the ability to react

Ability to drive, oxybutynine [2] ---> SmPC of [2] of EMA

Kentera may produce drowsiness, somnolence, or blurred vision

Ability to drive, oxycodone [2] ---> SmPC of [2] of eMC

Oxycodone can impair alertness and reactivity to such an extent that the ability to drive and operate machinery is affected or ceases altogether.

Ability to drive, oxymetazoline [2] ---> SmPC of [2] of eMC

No adverse effects known.

Ability to drive, oxytetracycline [2] ---> SmPC of [2] of eMC

None known.

Ability to drive, oxytocin [2] ---> SmPC of [2] of eMC

Oxytocin can induce labour, therefore caution should be exercised when driving or operating machines. Women with uterine contractions should not drive or use machines.

Ability to drive, paclitaxel [2] ---> SmPC of [2] of EMA

Abraxane may cause adverse reactions such as tiredness (very common) and dizziness (common) that may affect the ability to drive and use machinery.

Ability to drive, palbociclib [2] ---> SmPC of [2] of EMA

IBRANCE may cause fatigue and patients should exercise caution when driving or using machines.

Ability to drive, paliperidone [2] ---> SmPC of [2] of EMA

Paliperidone can have minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects

Ability to drive, palonosetron [2] ---> SmPC of [2] of EMA

Since palonosetron may induce dizziness, somnolence or fatigue, patients should be cautioned when driving or operating machines.

Ability to drive, pamidronate [2] ---> SmPC of [2] of eMC

Patients should be warned that somnolence and/or dizziness may occur following pamidronate infusion

Ability to drive, pamidronic acid [2] ---> SmPC of [2] of eMC

Patients should be warned that somnolence and/or dizziness may occur following pamidronate infusion

Ability to drive, pancuronium [2] ---> SmPC of [2] of eMC

It is not recommended to use potentially dangerous machinery or drive a car within 24 hours after full recovery from the neuromuscular blocking action of pancuronium.

Ability to drive, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) [2] ---> SmPC of [2

Some of the effects mentioned under section 4.8 "Undesirable Effects" may affect the ability to drive or use machines.

Ability to drive, panitumumab [2] ---> SmPC of [2] of EMA

Symptoms affecting their vision and/or ability to concentrate and react may occur

Ability to drive, panobinostat [2] ---> SmPC of [2] of EMA

Dizziness may occur following administration of Farydak

Ability to drive, pantoprazole [2] ---> SmPC of [2] of EMA

Dizziness and visual disturbances may occur

Ability to drive, parathyroid hormone [2] ---> SmPC of [2] of EMA

Patients with disturbances in cognition or attention should be advised to refrain from driving or using machines until symptoms have subsided.

Ability to drive, parecoxib [2] ---> SmPC of [2] of EMA

Dizziness, vertigo or somnolence may occur

Ability to drive, paroxetine [2] ---> SmPC of [2] of eMC

As with all psychoactive drugs, patients should be cautioned about their ability to drive a car and operate machinery.

Ability to drive, pasireotide [2] ---> SmPC of [2] of EMA

Patients should be advised to be cautious when driving or using machines if they experience fatigue or headache during treatment with Signifor.

Ability to drive, pazopanib [2] ---> SmPC of [2] of EMA

Patients should avoid driving or using machines if they feel dizzy, tired or weak

Ability to drive, peanut protein [2] ---> SmPC of [2] of EMA

Caution should be exercised for 2 hours after dosing in case any symptoms of an allergic reaction occur that could impact the ability to drive or use machines.

Ability to drive, pefloxacine

Patients should be advised that pefloxacin may have effects on the CNS

Ability to drive, pegaptanib [2] ---> SmPC of [2] of EMA

Macugen has a minor influence on the ability to drive and use machines due to the possible temporary visual blurring after administration of Macugen by intravitreal injection.

Ability to drive, pegaspargase [2] ---> SmPC of [2] of EMA

Patients should be advised not to drive or operate machines if they experience confusion or somnolence or other adverse reactions which can impair their ability to drive or operate machines.

Ability to drive, peginterferon alfa-2a [2] ---> SmPC of [2] of EMA

Pegasys has minor or moderate influence on the ability to drive and use machines. Patients who develop dizziness, confusion, somnolence or fatigue should be cautioned to avoid driving or operating machinery.

Ability to drive, peginterferon alfa-2b [2] ---> SmPC of [2] of EMA

Fatigue, somnolence or confusion may occur

Ability to drive, peginterferon beta-1a [2] ---> SmPC of [2] of EMA

Central nervous system-related adverse events associated with the use of interferon beta (e.g. nausea) might influence the patient's ability to drive or use machines

Ability to drive, pegloticase [2] ---> SmPC of [2] of EMA

If patients experience treatment-related symptoms affecting their ability to concentrate and react (i.e. headache or dizziness), it is recommended that they do not drive or use machines until the effect subsides.

Ability to drive, pegunigalsidase alfa [2] ---> SmPC of [2] of EMA

Dizziness or vertigo were observed in some patients following Elfabrio administration. These patients should refrain from driving or the use of machines until symptoms have subsided.

Ability to drive, pegvaliase [2] ---> SmPC of [2] of EMA

Palynziq has a minor influence on the ability to drive and use machines. Hypersensitivity reactions that include symptoms such as dizziness or syncope may affect the ability to drive and use machines.

Ability to drive, pembrolizumab [2] ---> SmPC of [2] of EMA

Fatigue has been reported following administration of pembrolizumab

Ability to drive, pemetrexed [2] ---> SmPC of [2] of EMA

Fatigue may occur

Ability to drive, pemigatinib [2] ---> SmPC of [2] of EMA

Adverse reactions such as fatigue and visual disturbances have been associated with pemigatinib. Therefore, caution should be recommended when driving or operating machines

Ability to drive, penbutolol

Changes in the ability to react

Ability to drive, pentaerythritol tetranitrate

It may alter the capacity to react

Ability to drive, pentamidine [2] ---> SmPC of [2] of eMC

Considering the risk of dizziness, one should be careful.

Ability to drive, pentazocine [2] ---> SmPC of [2] of eMC

Pentazocine may produce sedation, dizziness, and occasionally euphoria, so ambulant patients should be warned not to operate machinery or drive if affected.

Ability to drive, perampanel [2] ---> SmPC of [2] of EMA

Perampanel may cause dizziness and somnolence and, therefore, may influence the ability to drive or use machines.

Ability to drive, pergolide

Somnolence and/or sudden sleep episodes may occur. Pergolide can influence the ability to drive and use machines.

Ability to drive, perindopril [2] ---> SmPC of [2] of eMC

Individual reactions related to low blood pressure may occur in some patients

Ability to drive, perphenazine [2] ---> SmPC of [2] of eMC

Perphenazine may impair alertness, particularly when treatment is started. Perphenazine may cause sedation and patients should be advised not to drive or operate machinery.

Ability to drive, pertuzumab [2] ---> SmPC of [2] of EMA

Patients experiencing infusion reactions should be advised not to drive and use machines until symptoms abate.

Ability to drive, pertuzumab/trastuzumab [2] ---> SmPC of [2] of EMA

Patients experiencing injection-related reactions or dizziness (see section 4.4) should be advised not to drive and use machines until symptoms abate.

Ability to drive, pethidine [2] ---> SmPC of [2] of eMC

Pethidine causes drowsiness. If affected patients should not drive or operate machinery

Ability to drive, phenelzine [2] ---> SmPC of [2] of eMC

Produces adverse effects on driving ability.

Ability to drive, phenobarbital [2] ---> SmPC of [2] of eMC

Phenobarbital may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.

Ability to drive, phenothiazines [2] ---> SmPC of [2] of eMC

Phenothiazines may impair alertness and induce drowsiness especially at the start of treatment.

Ability to drive, phenoxybenzamine [2] ---> SmPC of [2] of eMC

None known.

Ability to drive, phenylbutazone

Fatigue and dizziness may occur

Ability to drive, phenylephrine

Blurred vision may occur

Ability to drive, phenylephrine/ketorolac [2] ---> SmPC of [2] of EMA

Omidria can have a major influence on the ability to drive and use machines. Patients should be advised not to drive or use machines until vision is clear.

Ability to drive, phenytoin [2] ---> SmPC of [2] of eMC

Caution is recommended in patients performing skilled tasks (e.g. driving or operating machinery) as treatment with phenytoin may cause central nervous system adverse effects such as dizziness and drowsiness

Ability to drive, pilocarpine [2] ---> SmPC of [2] of eMC

Pilocarpine has been reported to cause impairment of depth perception and visual blurring.

Ability to drive, pimozide [2] ---> SmPC of [2] of eMC

Pimozide may impair alertness, especially at the start of treatment.

Ability to drive, pindolol [2] ---> SmPC of [2] of eMC

Dizziness or fatigue may occur during initiation of treatment with beta-adrenoceptor blocking drugs

Ability to drive, pindolol/clopamide [2] ---> SmPC of [2] of eMC

Because dizziness or fatigue may occur during initiation of treatment with antihypertensive drugs, patients driving vehicles or operating machinery should exercise caution until their individual reaction to treatment has been determined.

Ability to drive, pioglitazone [2] ---> SmPC of [2] of EMA

Patients who experience visual disturbance should be cautious when driving or using machines.

Ability to drive, pioglitazone/glimepiride [2] ---> SmPC of [2] of EMA

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia from glimepiride or, for example, as a result of visual impairment.

Ability to drive, pioglitazone/metformin [2] ---> SmPC of [2] of EMA

Patients who experience visual disturbance should be cautious when driving or using machines.

Ability to drive, pipamperone

Changes in the ability to react

Ability to drive, piperacillin

In isolated cases there have been reports of seizures and anaphylactic shock

Ability to drive, pipotiazine [2] ---> SmPC of [2] of eMC

Patients should be warned about drowsiness especially at the start of treatment and advised not to drive or operate machinery.

Ability to drive, piracetam [2] ---> SmPC of [2] of eMC

Hyperkinesia, somnolence, nervousness and depression were reported more frequently in patients on piracetam than on placebo.

Ability to drive, pirenzepine

Abnormal accommodation may occur

Ability to drive, piretanide

Piretanide may cause reactions that decrease the ability to drive and use machines.

Ability to drive, pirfenidone [2] ---> SmPC of [2] of EMA

Esbriet may cause dizziness and fatigue, which could influence the ability to drive or use machines.

Ability to drive, piribedil

Piribedil may cause somnolence or sudden narcolepsy

Ability to drive, piritramide

Sedation may occur

Ability to drive, piroxicam [2] ---> SmPC of [2] of eMC

Undesirable effects such as dizziness, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs. If affected, patients should not drive or operate machinery.

Ability to drive, pitavastatin

Dizziness and somnolence have been reported during treatment

Ability to drive, pitolisant [2] ---> SmPC of [2] of EMA

Patients with abnormal levels of sleepiness who take pitolisant should be advised that their level of wakefulness may not return to normal.

Ability to drive, pizotifen [2] ---> SmPC of [2] of eMC

Pizotifen may cause drowsiness, somnolence, dizziness and other CNS effects.

Ability to drive, plerixafor [2] ---> SmPC of [2] of EMA

Some patients have experienced dizziness, fatigue or vasovagal reactions; therefore caution is advised when driving or operating machines.

Ability to drive, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [2] ---> SmPC of [2] of EMA

Some of the effects mentioned under section 4.8 "Undesirable effects" may temporarily affect the ability to drive or use machines.

Ability to drive, polatuzumab vedotin [2] ---> SmPC of [2] of EMA

Polivy has minor influence on the ability to drive and use machines. IRRs, PN, fatigue, and dizziness may occur during treatment with Polivy

Ability to drive, pomalidomide [2] ---> SmPC of [2] of EMA

Imnovid has minor or moderate influence on the ability to drive and use machines. Fatigue, depressed level of consciousness, confusion, and dizziness have been reported with the use of pomalidomide.

Ability to drive, ponatinib [2] ---> SmPC of [2] of EMA

Iclusig has a minor influence on the ability to drive and use machines. Adverse reactions such as lethargy, dizziness, and vision blurred have been associated with Iclusig.

Ability to drive, posaconazole [2] ---> SmPC of [2] of EMA

Since certain adverse reactions (e.g. dizziness, somnolence, etc.) have been reported with posaconazole use, which potentially may affect driving/operating machinery, caution needs to be used.

Ability to drive, potassium canrenoate

It may alter the capacity to react

Ability to drive, prajmalium

The ability to drive and use machines may be reduced

Ability to drive, pralsetinib [2] ---> SmPC of [2] of EMA

Caution should be exercised when driving or operating machines as patients may experience fatigue while taking Gavreto

Ability to drive, pramipexole [2] ---> SmPC of [2] of EMA

Hallucinations or somnolence can occur

Ability to drive, pravastatine [2] ---> SmPC of [2] of eMC

Dizziness and visual disturbances may occur during treatment.

Ability to drive, prazepam

Prazepam may cause sedation, amnesia, decreased ability to concentrate and impaired muscle function

Ability to drive, praziquantel

Praziquantel may impair alertness

Ability to drive, prazosin [2] ---> SmPC of [2] of eMC

The patient should be cautioned to avoid situations where injury could result should dizziness or weakness occur during the initiation of therapy

Ability to drive, pregabalin [2] ---> SmPC of [2] of EMA

Lyrica may have minor or moderate influence on the ability to drive and use machines. Lyrica may cause dizziness and somnolence and therefore may influence the ability to drive or use machines.

Ability to drive, pretomanid [2] ---> SmPC of [2] of EMA

Dizziness has been reported in some patients taking pretomanid and some patients experienced visual impairment. This should be considered when assessing a patient's ability to drive or operate machinery

Ability to drive, pridinol

Changes in the ability to react

Ability to drive, prilocaine [2] ---> SmPC of [2] of eMC

Local anaesthetics may have a very mild effect on mental function and co-ordination even in the absence of overt CNS toxicity, and may temporarily impair locomotion and alertness.

Ability to drive, primidone [2] ---> SmPC of [2] of eMC

As with most other anticonvulsants, patients who drive vehicles or operate machinery should be made aware of the possibility of impaired reaction time.

Ability to drive, probenecide

It has been reported that with probenecid may occur adverse reactions like somnolence, dizziness and ataxia

Ability to drive, procaine

Procain may impair the locomotor function and coordination

Ability to drive, procarbazine [2] ---> SmPC of [2] of eMC

Patients should be warned of the possibility of lethargy

Ability to drive, prochlorperazine [2] ---> SmPC of [2] of eMC

Patients who drive or operate machinery should be warned of the possibility of drowsiness.

Ability to drive, procyclidine [2] ---> SmPC of [2] of eMC

Adverse events of a neurological character such as blurred vision, dizziness, confusion and disorientation have been reported with procyclidine.

Ability to drive, progesterone

Somnolence may occur

Ability to drive, proglumetacine

Central nervous system (fatigue and dizziness) may occur

Ability to drive, promazine [2] ---> SmPC of [2] of eMC

Phenothiazines may impair alertness and induce drowsiness especially at the start of treatment.

Ability to drive, promethazine [2] ---> SmPC of [2] of eMC

Because the duration of action may be up to 12 hours, patients should be advised that if they feel drowsy they should not drive or operate heavy machinery.

Ability to drive, propafenone [2] ---> SmPC of [2] of eMC

Blurred vision, dizziness, fatigue and postural hypotension may affect the patient's speed of reaction and impair the individual's ability to operate machinery or motor vehicles.

Ability to drive, propantheline [2] ---> SmPC of [2] of eMC

Propantheline may produce drowsiness or blurred vision.

Ability to drive, propiverine [2] ---> SmPC of [2] of eMC

Propiverine hydrochloride may produce drowsiness and blurred vision.

Ability to drive, propofol [2] ---> SmPC of [2] of eMC

Patients should be advised that performance at skilled tasks, such as driving and operating machinery, may be impaired for some time after general anaesthesia.

Ability to drive, propranolol [2] ---> SmPC of [2] of eMC

Most beta-adrenoceptor blocking drugs, particularly lipophilic compounds, will pass into breast milk although to a variable extent. Breast feeding is therefore not recommended following administration of these compounds.

Ability to drive, prothionamide

Changes in the ability to react

Ability to drive, prothipendyl

Prothipendyl cause adverse reactions that decrease the ability to drive and use machines.

Ability to drive, proxymetacaine [2] ---> SmPC of [2] of eMC

It may cause transient blurring of vision on instillation. Warn patients not to drive or operate hazardous machinery unless vision is clear.

Ability to drive, prucalopride [2] ---> SmPC of [2] of EMA

Dizziness and fatigue have been observed in clinical studies, particularly during the first day of treatment

Ability to drive, pseudoephedrine [2] ---> SmPC of [2] of eMC

None stated.

Ability to drive, pyrazinamide [2] ---> SmPC of [2] of eMC

There are no data to suggest that pyrazinamide affects the ability to drive or use machines.

Ability to drive, pyridostigmine [2] ---> SmPC of [2] of eMC

Due to miosis and accommodation disorders caused by pyridostigmine or an inadequate treatment of myasthenia gravis, pyridostigmine may impair visual acuity and consequently the ability to react as well as the ability to drive and use machi

Ability to drive, pyritinol

Dizziness and fatigue may occur

Ability to drive, quazepam

The sedative effect affects the ability to drive or use machines

Ability to drive, quetiapine [2] ---> SmPC of [2] of eMC

Given its primary central nervous system effects, quetiapine may interfere with activities requiring mental alertness.

Ability to drive, quinagolide [2] ---> SmPC of [2] of eMC

Since, especially during the first days of treatment, hypotensive reactions may occasionally occur and result in reduced alertness, patients should be cautious when driving a vehicle or operating machinery.

Ability to drive, quinapril [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.

Ability to drive, quinine [2] ---> SmPC of [2] of eMC

Quinine may cause visual disturbances and vertigo

Ability to drive, quinolones

Fluoroquinolones may cause an impairment of the patient's ability to drive or operate machinery due to CNS reactions

Ability to drive, rabeprazole [2] ---> SmPC of [2] of eMC

Alertness is impaired due to somnolence; it is recommended that driving and operating complex machinery be avoided.

Ability to drive, raltegravir [2] ---> SmPC of [2] of EMA

Dizziness has been reported in some patients during treatment

Ability to drive, raltitrexed [2] ---> SmPC of [2] of eMC

Raltitrexed may cause malaise or asthenia following infusion and the ability to drive/use machinery could be impaired whilst such symptoms continue.

Ability to drive, ramipril [2] ---> SmPC of [2] of eMC

Some adverse effects (e.g. symptoms of a reduction in blood pressure such as dizziness) may impair the patient's ability to concentrate and react

Ability to drive, ramucirumab [2] ---> SmPC of [2] of EMA

If patients experience symptoms affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides.

Ability to drive, ranibizumab [2] ---> SmPC of [2] of EMA

The Lucentis treatment procedure may induce temporary visual disturbances, which may affect the ability to drive or use machines

Ability to drive, ranitidine

Headaches, dizziness, fatigue, restlessness and confusional states and hallucinations may occur

Ability to drive, ranolazine [2] ---> SmPC of [2] of EMA

Ranexa may cause dizziness, blurred vision, diplopia, confusional state, coordination abnormal, hallucination (see section 4.8), which may affect the ability to drive and use machines.

Ability to drive, rasagiline [2] ---> SmPC of [2] of EMA

Patients should be cautioned about operating hazardous machines, including motor vehicles, until they are reasonably certain that rasagiline does not affect them adversely.

Ability to drive, reboxetine [2] ---> SmPC of [2] of eMC

Any psychoactive drug can impair judgement or skills.

Ability to drive, recombinant salmon calcitonin [2] ---> SmPC of [2] of EMA

Injectable calcitonin may cause transient dizziness

Ability to drive, regadenoson [2] ---> SmPC of [2] of EMA

Dizziness, headache, and dyspnoea may occur

Ability to drive, regorafenib [2] ---> SmPC of [2] of EMA

If patients experience symptoms affecting their ability to concentrate and react during treatment with Stivarga, it is recommended that they do not drive or use machines until the effect subsides.

Ability to drive, remifentanil [2] ---> SmPC of [2] of eMC

If an early discharge is envisaged after application of remifentanil, following treatment using anaesthetic agents, patients should be advised not to drive or operate machinery

Ability to drive, remimazolam [2] ---> SmPC of [2] of EMA

Remimazolam has a major influence on the ability to drive and use machines. Prior to receiving remimazolam, the patient should be warned not to drive a vehicle or operate a machine until completely recovered.

Ability to drive, repaglinide [2] ---> SmPC of [2] of EMA

Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.

Ability to drive, reproterol

Changes in the ability to react

Ability to drive, respiratory syncytial virus vaccine [2] ---> SmPC of [2] of EMA

Arexvy has a minor influence on the ability to drive and use machines. Some of the effects mentioned under section 4.8 "Undesirable effects" (e.g. fatigue) may temporarily affect the ability to drive or use machines.

Ability to drive, retigabine [2] ---> SmPC of [2] of EMA

Adverse reactions such as dizziness, somnolence, diplopia and blurred vision were reported in controlled clinical studies, particularly during titration

Ability to drive, retinoids ---> SmPC of [alitretinoin] of eMC

Decreased night vision has been reported in patients treated with retinoids.

Ability to drive, ribavirin [2] ---> SmPC of [2] of EMA

Patients who develop fatigue, somnolence, or confusion during treatment must be cautioned to avoid driving or operating machinery.

Ability to drive, ribociclib [2] ---> SmPC of [2] of EMA

Patients should be advised to be cautious when driving or using machines in case they experience fatigue during treatment with Kisqali

Ability to drive, rifampicin [2] ---> SmPC of [2] of eMC

No studies on the effects on the ability to drive and use machines have been performed.

Ability to drive, rilonacept [2] ---> SmPC of [2] of EMA

Vertigo may occur

Ability to drive, rilpivirine [2] ---> SmPC of [2] of EMA

Fatigue, dizziness and somnolence have been reported in some patients taking EDURANT and should be considered when assessing a patient's ability to drive or operate machinery.

Ability to drive, riluzole [2] ---> SmPC of [2] of EMA

Patients should be warned about the potential for dizziness or vertigo, and advised not to drive or operate machinery if these symptoms occur.

Ability to drive, rimexolone [2] ---> SmPC of [2] of eMC

If blurred vision or visual disturbances occur, the patient must wait until the vision clears before driving or using machinery.

Ability to drive, riociguat [2] ---> SmPC of [2] of EMA

Dizziness has been reported and may affect the ability to drive and use machines

Ability to drive, ripretinib [2] ---> SmPC of [2] of EMA

In some patients, fatigue has been reported following administration of QINLOCK. If a patient experiences fatigue, this may influence their ability to drive or use machines.

Ability to drive, risperidone [2] ---> SmPC of [2] of EMA

Patients should be advised not to drive or operate machinery until their individual susceptibility is known.

Ability to drive, ritonavir [2] ---> SmPC of [2] of EMA

Dizziness is a known undesirable effect that should be taken into account when driving or using machinery.

Ability to drive, rivaroxaban [2] ---> SmPC of [2] of EMA

Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported. Patients experiencing these adverse reactions should not drive or use machines.

Ability to drive, rivastigmine [2] ---> SmPC of [2] of EMA

Alzheimer's disease may cause gradual impairment of driving performance or compromise the ability to use machinery. Furthermore, rivastigmine can induce dizziness and somnolence, mainly when initiating treatment or increasing the dose.

Ability to drive, rizatriptan [2] ---> SmPC of [2] of eMC

Migraine or the treatment may cause somnolence in some patients. Dizziness has also been reported

Ability to drive, rocuronium [2] ---> SmPC of [2] of eMC

Since this medicine is used as an adjunct to general anaesthesia, the usual precautionary measures after a general anaesthesia should be taken for ambulatory patients.

Ability to drive, rolapitant [2] ---> SmPC of [2] of EMA

Varuby has minor influence on the ability to drive and use machines. Dizziness and fatigue may occur following administration of rolapitant

Ability to drive, romiplostim [2] ---> SmPC of [2] of EMA

Nplate has moderate influence on the ability to drive and use machines. In clinical trials, mild to moderate, transient bouts of dizziness were experienced by some patients.

Ability to drive, ropeginterferon alfa-2b [2] ---> SmPC of [2] of EMA

Besremi has minor influence on the ability to drive and use machines. Patients who experience dizziness, somnolence or hallucination (see section 4.8) during Besremi therapy should avoid driving or using machines.

Ability to drive, ropinirole [2] ---> SmPC of [2] of eMC

Somnolence and/or sudden sleep episodes may occur

Ability to drive, ropivacaine [2] ---> SmPC of [2] of eMC

Depending on the dose, local anaesthetics may have a minor influence on mental function and co-ordination even in the absence of overt CNS toxicity and may temporarily impair locomotion and alertness.

Ability to drive, rosiglitazone/glimepiride [2] ---> SmPC of [2] of EMA

The potential for hypoglycaemia should be borne in mind

Ability to drive, rosuvastatin [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment.

Ability to drive, rotigotine [2] ---> SmPC of [2] of EMA

Somnolence and/or sudden sleep episodes may occur

Ability to drive, roxadustat [2] ---> SmPC of [2] of EMA

Seizures have been reported during treatment with Evrenzo (see section 4.4). Therefore, caution should be exercised when driving or using machines.

Ability to drive, roxithromycin

Dizziness may occur

Ability to drive, rucaparib [2] ---> SmPC of [2] of EMA

Rubraca has minor influence on the ability to drive and use machines. Caution when driving or using machines is advised for patients who report fatigue, nausea, or dizziness during treatment with Rubraca

Ability to drive, rufinamide [2] ---> SmPC of [2] of EMA

Inovelon may cause dizziness, somnolence and blurred vision.

Ability to drive, rupatadine [2] ---> SmPC of [2] of eMC

Care should be taken before driving or using machinery until the patient's individual reaction on rupatadine has been established.

Ability to drive, ruxolitinib [2] ---> SmPC of [2] of EMA

Jakavi has no or negligible sedating effect. However, patients who experience dizziness after the intake of Jakavi should refrain from driving or using machines.

Ability to drive, sacituzumab govitecan [2] ---> SmPC of [2] of EMA

Sacituzumab govitecan has minor influence on the ability to drive and use machines, e.g. dizziness, fatigue

Ability to drive, sacubitril/valsartan [2] ---> SmPC of [2] of EMA

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or fatigue may occur.

Ability to drive, safinamide [2] ---> SmPC of [2] of EMA

Patients should be cautioned about using hazardous machines, including motor vehicles, until they are reasonably certain that safinamide does not affect them adversely.

Ability to drive, saquinavir [2] ---> SmPC of [2] of EMA

Invirase may have a minor influence on the ability to drive and use machines. Dizziness, fatigue and visual impairment have been reported during treatment with Invirase.

Ability to drive, saxagliptin [2] ---> SmPC of [2] of EMA

When driving or using machines, it should be taken into account that dizziness has been reported in studies with saxagliptin.

Ability to drive, saxagliptin/dapagliflozin [2] ---> SmPC of [2] of EMA

When driving or using machines, it should be taken into account that dizziness has been reported in studies with combined use of saxagliptin and dapagliflozin.

Ability to drive, saxagliptin/metformin [2] ---> SmPC of [2] of EMA

Dizziness has been reported in studies with saxagliptin. In addition, patients should be alerted to the risk of hypoglycaemia when Komboglyze is used in combination with other antidiabetic medicinal products known to cause hypoglycaemia

Ability to drive, scopolamine

The administration of scopolamine may cause confusion, blurred vision due to accommodation paralysis, somnolence, etc.

Ability to drive, selegiline [2] ---> SmPC of [2] of eMC

Selegiline has major influence (e.g may cause dizziness) on the ability to drive and use machines, therefore patients should avoid these activities.

Ability to drive, selexipag [2] ---> SmPC of [2] of EMA

The clinical status of the patient and the adverse reaction profile of selexipag (such as headache or hypotension) should be kept in mind when considering the patient's ability to drive and use machines.

Ability to drive, selinexor [2] ---> SmPC of [2] of EMA

Selinexor can cause fatigue, confusional state and dizziness. Patients should be advised not to drive or operate machines if they experience any of these symptoms.

Ability to drive, selpercatinib [2] ---> SmPC of [2] of EMA

Patients should be advised to be cautious when driving or using machines in case they experience fatigue or dizziness during treatment with Retsevmo

Ability to drive, selumetinib [2] ---> SmPC of [2] of EMA

Fatigue, asthenia and visual disturbances have been reported during treatment with selumetinib and patients who experience these symptoms should observe caution when driving or using machines.

Ability to drive, sertindole

Patients should be advised not to drive or operate machinery until their individual susceptibility is known.

Ability to drive, sertraline [2] ---> SmPC of [2] of EMA

Psychotropic drugs may impair the mental or physical abilities required for the performance of potentially hazardous

Ability to drive, sevoflurane [2] ---> SmPC of [2] of eMC

As with other agents, patients should be advised that performance of activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, may be impaired for some time after general anaesthesia

Ability to drive, sibutramine [2] ---> SmPC of [2] of eMC

Any centrally-acting drug may impair judgement, thinking or motor skills.

Ability to drive, sildenafil [2] ---> SmPC of [2] of EMA

As dizziness and altered vision were reported in clinical trials with sildenafil, patients should be aware of how they react to Vizarsin, before driving or operating machinery.

Ability to drive, silodosin [2] ---> SmPC of [2] of EMA

Patients should be informed about the possible occurrence of symptoms related to postural hypotension (such as dizziness)

Ability to drive, simvastatine [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines, it should be taken into account that dizziness has been reported rarely in post-marketing experiences.

Ability to drive, siponimod [2] ---> SmPC of [2] of EMA

Dizziness may occasionally occur when initiating therapy with siponimod. Therefore, patients should not drive or use machines during the first day of treatment initiation with siponimod

Ability to drive, sipuleucel

Sipuleucel may cause fatigue, dizziness, syncope, chills, and headache

Ability to drive, sitagliptin [2] ---> SmPC of [2] of EMA

When driving or using machines, it should be taken into account that dizziness and somnolence have been reported.

Ability to drive, sitagliptin/metformin [2] ---> SmPC of [2] of EMA

When driving or using machines, it should be taken into account that dizziness and somnolence have been reported with sitagliptin.

Ability to drive, sitaxentan [2] ---> SmPC of [2] of EMA

A known undesirable effect is dizziness, which could influence the ability to drive or use machines.

Ability to drive, smallpox vaccine (Live Modified Vaccinia Virus Ankara) [2] ---> SmPC of [2] of EMA

Some of the undesirable effects may affect the ability to drive or operate machinery (e.g. dizziness).

Ability to drive, sodium nitroprusside

Disorientation, dizziness and blurred vision may occur

Ability to drive, sodium oxybate [2] ---> SmPC of [2] of EMA

For at least 6 hours after taking sodium oxybate, patients must not undertake activities requiring complete mental alertness or motor co-ordination

Ability to drive, sodium valproate [2] ---> SmPC of [2] of eMC

Patients should be warned of the risk of transient drowsiness, especially in cases of anticonvulsant polytherapy or association with benzodiazepines

Ability to drive, sofosbuvir [2] ---> SmPC of [2] of EMA

Patients should be informed that fatigue and disturbance in attention, dizziness and blurred vision have been reported during treatment with sofosbuvir in combination with peginterferon alfa and ribavirin

Ability to drive, solifenacin [2] ---> SmPC of [2] of eMC

Since solifenacin, like other anticholinergics may cause blurred vision, and, uncommonly, somnolence and fatigue, the ability to drive and use machines may be negatively affected

Ability to drive, solriamfetol [2] ---> SmPC of [2] of EMA

Dizziness and disturbance in attention may occur following administration of solriamfetol. Patients with abnormal levels of sleepiness who take solriamfetol should be advised that their level of wakefulness may not return to normal.

Ability to drive, sotagliflozin [2] ---> SmPC of [2] of EMA

Sotagliflozin has no or negligible influence on the ability to drive and use machines. However, patients should be alerted to the risk of hypoglycaemia as sotagliflozin is used in combination with insulin.

Ability to drive, sotalol [2] ---> SmPC of [2] of eMC

There are no data available, but the occasional occurrence of side-effects such as dizziness and fatigue should be taken into account

Ability to drive, spheroids/cm2 implantation suspension [2] ---> SmPC of [2] of EMA

Due to the surgical nature of the underlying procedure, implantation of Spherox has a major influence on the ability to drive and use machines.

Ability to drive, spironolactone [2] ---> SmPC of [2] of eMC

Patients should be warned that they may experience dizziness or drowsiness when taking this medicine.

Ability to drive, stavudine [2] ---> SmPC of [2] of EMA

Stavudine may cause dizziness and/or somnolence.

Ability to drive, stiripentol [2] ---> SmPC of [2] of EMA

Stiripentol may cause dizziness and ataxia that may affect ability to drive and use machines and patients should not drive or use machinery whilst on stiripentol therapy.

Ability to drive, succinimides

The ability to drive and use machines may be impaired

Ability to drive, succinylcholine [2] ---> SmPC of [2] of eMC

Suxamethonium will always be used in combination with a general anaesthetic and therefore the usual precautions relating to performance of tasks following general anaesthesia apply.

Ability to drive, sufentanil [2] ---> SmPC of [2] of EMA

Patients should only drive and use machines if sufficient time has elapsed after the last administration of Zalviso.

Ability to drive, sulfacetamide

This medicinal product can affect the visual acuity

Ability to drive, sulpiride [2] ---> SmPC of [2] of eMC

Even used as recommended, sulpiride may cause sedation so that the ability to drive vehicles or operate machinery can be impaired.

Ability to drive, sultiame

Changes in the ability to react

Ability to drive, sumatriptan [2] ---> SmPC of [2] of eMC

Drowsiness may occur as a result of migraine or its treatment with sumatriptan.

Ability to drive, sunitinib [2] ---> SmPC of [2] of EMA

Patients should be advised that they may experience dizziness during treatment with sunitinib.

Ability to drive, suxamethonium [2] ---> SmPC of [2] of eMC

Suxamethonium will always be used in combination with a general anaesthetic and therefore the usual precautions relating to performance of tasks following general anaesthesia apply.

Ability to drive, tabelecleucel [2] ---> SmPC of [2] of EMA

Ebvallo has minor influence on the ability to drive and use machines, e.g. dizziness, fatigue (see section 4.8).

Ability to drive, tacrolimus [2] ---> SmPC of [2] of EMA

Tacrolimus may cause visual and neurological disturbances. This effect may be enhanced if tacrolimus is administered in association with alcohol.

Ability to drive, tadalafil [2] ---> SmPC of [2] of EMA

Although the frequency of reports of dizziness in placebo and tadalafil arms in clinical trials was similar, patients should be aware of how they react to CIALIS, before driving or using machines.

Ability to drive, tafluprost [2] ---> SmPC of [2] of eMC

As with any ocular treatment, if transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machinery.

Ability to drive, talazoparib [2] ---> SmPC of [2] of EMA

Talzenna may have a minor influence on the ability to drive and use machines. Fatigue/asthenia or dizziness may occur following administration of talazoparib.

Ability to drive, talimogene laherparepvec [2] ---> SmPC of [2] of EMA

Because of potential adverse reactions such as dizziness and confusional state (see section 4.8), patients should be advised to use caution when driving or operating machinery

Ability to drive, talinolol

Changes in the ability to react

Ability to drive, tamoxifen [2] ---> SmPC of [2] of eMC

Since visual disturbances and light-headedness have been observed commonly with the use of tamoxifen, caution is advised when driving or using machines.

Ability to drive, tamsulosin [2] ---> SmPC of [2] of eMC

Patients should be aware of the fact that dizziness can occur.

Ability to drive, tapentadol [2] ---> SmPC of [2] of eMC

Tapentadol may have major influence on the ability to drive and use machines because it may adversely affect central nervous system functions

Ability to drive, tasimelteon [2] ---> SmPC of [2] of EMA

Tasimelteon may cause somnolence.

Ability to drive, tedizolid [2] ---> SmPC of [2] of EMA

It may cause dizziness, fatigue or, uncommonly, somnolence

Ability to drive, teduglutide [2] ---> SmPC of [2] of EMA

Cases of syncope have been reported in clinical studies. Such events might impact the ability to drive and use machines

Ability to drive, tegafur

Vertigo, nauseas and disorientation may occur

Ability to drive, tegafur/gimeracil/oteracil [2] ---> SmPC of [2] of EMA

Teysuno has moderate influence on the ability to drive and use machines as fatigue, dizziness, blurred vision, and nausea are common adverse reactions of Teysuno in combination with cisplatin.

Ability to drive, tegafur/uracil

Confusedness may occur

Ability to drive, teicoplanin [2] ---> SmPC of [2] of eMC

Teicoplanin can cause dizziness and headache.

Ability to drive, telaprevir [2] ---> SmPC of [2] of EMA

Syncope and retinopathy have been reported in some patients

Ability to drive, telavancin [2] ---> SmPC of [2] of EMA

Dizziness, somnolence, confusion and blurred vision may occur and these may have an influence on the ability to drive and use machines

Ability to drive, telithromycin [2] ---> SmPC of [2] of EMA

Ketek may cause adverse reactions such as visual disturbances, confusion or hallucination which may reduce the capacity for the completion of certain tasks.

Ability to drive, telmisartan [2] ---> SmPC of [2] of EMA

When driving vehicles or operating machinery it should be taken into account that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy such as Telmisartan Actavis.

Ability to drive, telmisartan/amlodipine [2] ---> SmPC of [2] of EMA

Patients should be advised that they may experience adverse reactions such as syncope, somnolence, dizziness, or vertigo during treatment

Ability to drive, telmisartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

When driving vehicles or operating machinery it should be taken into account that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy such as MicardisPlus.

Ability to drive, telotristat ethyl [2] ---> SmPC of [2] of EMA

Fatigue may occur following administration of telotristat

Ability to drive, temazepam [2] ---> SmPC of [2] of eMC

Patients should be advised that sedation, amnesia, impaired concentration, dizziness, blurred vision and impaired muscular function may occur

Ability to drive, temoporfin [2] ---> SmPC of [2] of EMA

To avoid photosensitivity problems, it is advised not to drive during the first 15 days after injection, and after under subdued lighting conditions

Ability to drive, temozolomide [2] ---> SmPC of [2] of EMA

Fatigue and somnolence may occur

Ability to drive, temsirolimus [2] ---> SmPC of [2] of EMA

The amount of alcohol in this medicinal product may impair your ability to drive or use machines

Ability to drive, teniposide

The ability to drive a vehicle or to operate machinery may be impaired

Ability to drive, tenofovir alafenamide [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness has been reported during treatment with Vemlidy.

Ability to drive, tenofovir disoproxil [2] ---> SmPC of [2] of EMA

Patients should be informed that dizziness has been reported during treatment with tenofovir disoproxil fumarate.

Ability to drive, tenoxicam

Rotatory vertigo or vision disorders may occur

Ability to drive, terazosine [2] ---> SmPC of [2] of eMC

Dizziness, light-headedness or drowsiness may occur with the initial dose

Ability to drive, terbinafine [2] ---> SmPC of [2] of eMC

Patients who experience dizziness as an undesirable effect should avoid driving vehicles or using machines.

Ability to drive, terbutaline

The ability to drive and use machines may be reduced

Ability to drive, teriflunomide [2] ---> SmPC of [2] of EMA

In the case of adverse reactions such as dizziness, which has been reported with leflunomide, the parent compound, the patient's ability to concentrate and to react properly may be impaired.

Ability to drive, teriparatide [2] ---> SmPC of [2] of EMA

Transient, orthostatic hypotension or dizziness was observed in some patients. These patients should refrain from driving or the use of machines until symptoms have subsided.

Ability to drive, terizidone

Changes in the ability to react

Ability to drive, testosterone [2] ---> SmPC of [2] of EMA

Migraine, insomnia, disturbance in attention and diplopia may occur

Ability to drive, tetrabenazine

Patients should be advised that tetrabenazine may cause drowsiness

Ability to drive, tetracosactide [2] ---> SmPC of [2] of eMC

Patients should be warned of the potential hazards of driving or operating machinery if they experience side effects such as dizziness.

Ability to drive, tetracyclines

Headache, dizziness, visual disturbances may occur

Ability to drive, tetrazepam

The sedative effect affects the ability to drive or use machines

Ability to drive, tetryzoline

Blurred vision may occur

Ability to drive, tezacaftor/ivacaftor [2] ---> SmPC of [2] of EMA

Patients experiencing dizziness should be advised not to drive or use machines until symptoms abate.

Ability to drive, thalidomide [2] ---> SmPC of [2] of EMA

Thalidomide may cause fatigue, dizziness, somnolence and blurred vision

Ability to drive, theophylline [2] ---> SmPC of [2] of eMC

No known effects.

Ability to drive, thiethylperazine

Somnolence may occur

Ability to drive, thiopental [2] ---> SmPC of [2] of eMC

Post-operative vertigo, disorientation and sedation may be prolonged and out-patients given thiopental sodium should therefore be advised not to drive or use machinery, especially within the first 24 to 36 hours.

Ability to drive, thioridazine

Blurred sight and somnolence may occur

Ability to drive, thiotepa [2] ---> SmPC of [2] of EMA

TEPADINA may have major influence on the ability to drive and use machines. It is likely that certain adverse reactions of thiotepa like dizziness, headache and blurred vision could affect these functions.

Ability to drive, thyrotropin

Dizziness and headaches may occur

Ability to drive, thyrotropin alfa [2] ---> SmPC of [2] of EMA

Thyrogen may reduce the ability to drive or use machines, since dizziness and headaches have been reported.

Ability to drive, tiagabine [2] ---> SmPC of [2] of eMC

Tiagabine may cause dizziness or other CNS related symptoms, especially during initial treatment.

Ability to drive, tianeptine

Psychomotility can be affected in some patients

Ability to drive, tiapride

Tiapride acts on the central nervous system and can cause somnolence, dizziness, visual alterations and decreased ability to react

Ability to drive, tiaprofenic acid [2] ---> SmPC of [2] of eMC

Undesirable effects such as dizziness, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs.

Ability to drive, ticagrelor [2] ---> SmPC of [2] of EMA

During treatment with ticagrelor, dizziness and confusion have been reported. Therefore, patients who experience these symptoms should be cautious while driving or using machines.

Ability to drive, ticlopidine

Dizziness may occur

Ability to drive, tigecycline [2] ---> SmPC of [2] of EMA

Dizziness may occur and this may have an effect on driving and use of machines

Ability to drive, tilidine

Changes in the ability to react

Ability to drive, timolol [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or fatigue may occur.

Ability to drive, tinidazole [2] ---> SmPC of [2] of eMC

Dizziness, vertigo, ataxia, peripheral neuropathy may occur

Ability to drive, tiotropium [2] ---> SmPC of [2] of eMC

The occurrence of dizziness, blurred vision, or headache may influence the ability to drive and use machinery.

Ability to drive, tipranavir [2] ---> SmPC of [2] of EMA

Dizziness, somnolence, and fatigue have been reported in some patients

Ability to drive, tipranavir/ritonavir ---> SmPC of [tipranavir] of EMA

Dizziness, somnolence, and fatigue have been reported in some patients

Ability to drive, tirzepatide [2] ---> SmPC of [2] of EMA

When tirzepatide is used in combination with a sulphonylurea or insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines

Ability to drive, tisagenlecleucel [2] ---> SmPC of [2] of EMA

Due to the potential for neurological events, including altered mental status or seizures, patients receiving Kymriah are at risk for altered or decreased consciousness or coordination in the 8 weeks following infusion.

Ability to drive, tivozanib [2] ---> SmPC of [2] of EMA

Patients should be advised to be cautious when driving or using machines if they experience asthenia, fatigue, and/or dizziness during treatment with tivozanib

Ability to drive, tizanidine [2] ---> SmPC of [2] of eMC

Patients experiencing somnolence, dizziness or any signs or symptoms of hypotension should refrain from activities requiring a high degree of alertness, e.g. driving a vehicle or operating machines.

Ability to drive, tobramycin [2] ---> SmPC of [2] of EMA

On the basis of the pharmacodynamic profile and reported adverse drug reactions, TOBI Podhaler is not expected to adversely affect the ability to drive and use machines.

Ability to drive, tocilizumab [2] ---> SmPC of [2] of EMA

RoActemra has minor influence on the ability to drive and use machines (see section 4.8, dizziness).

Ability to drive, tolcapone [2] ---> SmPC of [2] of EMA

The ability to drive and operate machines may be compromised due to the Parkinson's disease symptoms. Levodopa has been associated with somnolence and episodes of sudden sleep onset.

Ability to drive, tolterodine [2] ---> SmPC of [2] of eMC

Since this drug may cause accommodation disturbances and influence reaction time, the ability to drive and use machines may be negatively affected.

Ability to drive, tolvaptan [2] ---> SmPC of [2] of EMA

When driving vehicles or using machines it should be taken into account that occasionally dizziness, asthenia or syncope may occur.

Ability to drive, topiramate [2] ---> SmPC of [2] of eMC

Topiramate acts on the central nervous system and may produce drowsiness, dizziness or other related symptoms.

Ability to drive, topotecan [2] ---> SmPC of [2] of EMA

Caution should be observed when driving or operating machines if fatigue and asthenia persist.

Ability to drive, torasemid [2] ---> SmPC of [2] of eMC

As for other drugs which produce changes in blood pressure, patients taking torasemide should be warned not to drive or operate machinery if they experience dizziness or related symptoms.

Ability to drive, trabectedin [2] ---> SmPC of [2] of EMA

Fatigue and/or asthenia have been reported in patients receiving trabectedin. Patients who experience any of these adverse reactions during therapy must not drive or operate machines.

Ability to drive, tramadol [2] ---> SmPC of [2] of eMC

Tramadol may cause drowsiness and this effect may be potentiated by alcohol and other CNS depressants. Ambulant patients should be warned not to drive or operate machinery if affected.

Ability to drive, trametinib [2] ---> SmPC of [2] of EMA

The clinical status of the patient and the adverse reaction profile (fatigue, dizziness or eye problems) should be borne in mind when considering the patient's ability to perform tasks that require judgment, motor and cognitive skills.

Ability to drive, trandolapril [2] ---> SmPC of [2] of eMC

ACE inhibitors may affect the ability to drive or operate machinery, particularly at the start of treatment, when changing over from other medication or during concomitant use of alcohol.

Ability to drive, trandolapril/verapamil [2] ---> SmPC of [2] of eMC

There are no data available, but an effect cannot be ruled out, since the undesirable effects such as dizziness and fatigue can occur.

Ability to drive, tranylcypromine [2] ---> SmPC of [2] of eMC

Tranylcypromine may affect the ability to drive and operate machinery. Patients should not undertake such activities unless it has been shown not to affect mental or physical capacity.

Ability to drive, trapidil

Changes in the ability to react

Ability to drive, trastuzumab emtansine [2] ---> SmPC of [2] of EMA

The significance of reported adverse reactions such as fatigue, headache, dizziness and blurred vision on the ability to drive or use machines is unknown.

Ability to drive, trastuzumab [2] ---> SmPC of [2] of EMA

Patients experiencing infusion-related symptoms should be advised not to drive and use machines until symptoms abate.

Ability to drive, travoprost [2] ---> SmPC of [2] of EMA

Blurred vision may occur

Ability to drive, travoprost/timolol [2] ---> SmPC of [2] of EMA

As with any eye drop, temporary blurred vision or other visual disturbances may occur.

Ability to drive, trazodone [2] ---> SmPC of [2] of eMC

Patients should be cautioned against the risks of driving or operating machinery until they are sure they are not affected by drowsiness, sedation, dizziness, confusional states, or blurred vision.

Ability to drive, treosulfan [2] ---> SmPC of [2] of EMA

Treosulfan has moderate influence on the ability to drive and use machines. It is likely that certain adverse reactions of treosulfan like nausea, vomiting or dizziness could affect these functions.

Ability to drive, treprostinil

Treprostinil has minor influence on the ability to drive and use machines at the initiation of treatment or dose adjustments. They may be accompanied by undesirable effects such as symptomatic systemic hypotension or dizziness

Ability to drive, triazolam

Drowsiness or dizziness may occur

Ability to drive, trifluoperazine [2] ---> SmPC of [2] of eMC

Trifluoperazine may cause side effects including drowsiness, dizziness and visual disturbances

Ability to drive, trifluridine

Possible decrease of visual acuity

Ability to drive, trifluridine/tipiracil [2] ---> SmPC of [2] of EMA

Lonsurf has minor influence on the ability to drive and use machines. Fatigue, dizziness or malaise may occur during treatment

Ability to drive, trihexyphenidyl [2] ---> SmPC of [2] of eMC

Can cause blurring of vision, dizziness and mild nausea. Also mental confusion in some cases.

Ability to drive, trimetazidine

Dizziness and somnolence may occur

Ability to drive, trimipramine [2] ---> SmPC of [2] of eMC

Trimipramine may initially impair alertness. Patients should be warned of the possible hazard when driving or operating machinery.

Ability to drive, triptorelin [2] ---> SmPC of [2] of eMC

The ability to drive and use machines may be impaired should the patient experience dizziness, somnolence and visual disturbances (being possible undesirable effects of treatment), or resulting from the underlying disease.

Ability to drive, tropicamide [2] ---> SmPC of [2] of eMC

Patients who receive a mydriatic may suffer from photophobia and this may impair their ability to drive under certain circumstances.

Ability to drive, tropisetron

Dizziness and tiredness may occur

Ability to drive, trospium [2] ---> SmPC of [2] of eMC

Principally, disorders of accommodation can lower the ability to actively participate in road traffic and to use machines.

Ability to drive, tucatinib [2] ---> SmPC of [2] of EMA

The clinical status of the patient should be considered when assessing the patient's ability to perform tasks that require judgment, motor, or cognitive skills.

Ability to drive, ulipristal [2] ---> SmPC of [2] of EMA

Mild dizziness has been observed after ulipristal acetate intake.

Ability to drive, unoprostone

Visual disturbances may occur

Ability to drive, urapidil

It may alter the capacity to react

Ability to drive, valaciclovir [2] ---> SmPC of [2] of eMC

The clinical status of the patient and the adverse reaction profile should be borne in mind when considering the patient`s ability to drive or operate machinery.

Ability to drive, valdecoxib [2] ---> SmPC of [2] of EMA

Patients who experience dizziness, vertigo or somnolence during treatment with valdecoxib should refrain from driving or operating machinery.

Ability to drive, valganciclovir [2] ---> SmPC of [2] of eMC

Convulsions, sedation, dizziness, ataxia, and/or confusion have been reported with the use of valganciclovir and/or ganciclovir.

Ability to drive, valproic acid [2] ---> SmPC of [2] of eMC

Patients should be warned of the risk of transient drowsiness, especially in cases of anticonvulsant polytherapy or association with benzodiazepines

Ability to drive, valsartan [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.

Ability to drive, valsartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.

Ability to drive, vandetanib [2] ---> SmPC of [2] of EMA

Fatigue and blurred vision have been reported

Ability to drive, vardenafil [2] ---> SmPC of [2] of EMA

As dizziness and abnormal vision have been reported in clinical trials with vardenafil, patients should be aware of how they react to Vivanza, before driving or operating machines.

Ability to drive, varenicline [2] ---> SmPC of [2] of EMA

CHAMPIX may cause dizziness and somnolence and therefore may influence the ability to drive and use machines.

Ability to drive, vecuronium [2] ---> SmPC of [2] of eMC

Since vecuronium bromide is used as an adjunct to general anaesthesia, the usual precautionary measures after a general anaesthesia should be taken for ambulatory patients.

Ability to drive, vedolizumab [2] ---> SmPC of [2] of EMA

Dizziness has been reported in a small number of patients.

Ability to drive, vemurafenib [2] ---> SmPC of [2] of EMA

Patients should be made aware of the potential fatigue or eye problems that could be a reason for not driving.

Ability to drive, venetoclax [2] ---> SmPC of [2] of EMA

Fatigue has been reported in some patients taking Venclyxto and should be considered when assessing a patient's ability to drive or operate machines.

Ability to drive, venlafaxine [2] ---> SmPC of [2] of eMC

Any psychoactive medicinal product may impair judgment, thinking, and motor skills.

Ability to drive, verapamil [2] ---> SmPC of [2] of eMC

Depending on individual susceptibility, the patient's ability to drive a vehicle or operate machinery or work under hazardous conditions may be impaired.

Ability to drive, vernakalant [2] ---> SmPC of [2] of EMA

BRINAVESS has a minor to moderate influence on the ability to drive and use machines. Dizziness has been reported within the first two hours after receiving BRINAVESS

Ability to drive, verteporfin [2] ---> SmPC of [2] of EMA

Patients may develop transient visual disturbances such as abnormal vision, vision decrease, or visual field defects

Ability to drive, vigabatrin [2] ---> SmPC of [2] of eMC

Visual field defects which can significantly affect the ability to drive and use machines have been frequently reported

Ability to drive, vildagliptin [2] ---> SmPC of [2] of EMA

Patients who experience dizziness as an adverse reaction should avoid driving vehicles or using machines.

Ability to drive, vildagliptin/metformin [2] ---> SmPC of [2] of EMA

Patients who may experience dizziness as an adverse reaction should avoid driving vehicles or using machines.

Ability to drive, vinblastine [2] ---> SmPC of [2] of eMC

None known.

Ability to drive, vinca alkaloids

Changes in the ability to react

Ability to drive, vincristine [2] ---> SmPC of [2] of eMC

Not known.

Ability to drive, vindesine

CNS-related adverse events.

Ability to drive, vinflunine [2] ---> SmPC of [2] of EMA

Vinflunine may cause adverse reactions such as fatigue (very common) and dizziness (common) which may lead to a minor or moderate influence on the ability to drive and use machines.

Ability to drive, vinorelbine [2] ---> SmPC of [2] of eMC

Caution is necessary in patient treated with vinorelbine considering some adverse effects of the drug.

Ability to drive, voretigene neparvovec [2] ---> SmPC of [2] of EMA

Voretigene neparvovec has minor influence on the ability to drive and use machines. Patients may experience temporary visual disturbances after receiving subretinal injection of Luxturna.

Ability to drive, voriconazole [2] ---> SmPC of [2] of EMA

VFEND has moderate influence on the ability to drive and use machines. It may cause transient and reversible changes to vision, including blurring, altered/enhanced visual perception and/or photophobia.

Ability to drive, vosoritide [2] ---> SmPC of [2] of EMA

The patient's response to treatment should be considered and if appropriate, advised not to drive, cycle or use machines for at least 60 minutes after injection.

Ability to drive, voxelotor [2] ---> SmPC of [2] of EMA

Oxbryta has no or negligible influence on the ability to drive and use machines.

Ability to drive, xipamide [2] ---> SmPC of [2] of eMC

None known.

Ability to drive, xylometazoline [2] ---> SmPC of [2] of eMC

None.

Ability to drive, yohimbine

The ability to drive a vehicle or to operate machinery may be impaired

Ability to drive, zaleplon [2] ---> SmPC of [2] of EMA

Sedation, amnesia, impaired concentration and impaired muscular function may occur

Ability to drive, zanubrutinib [2] ---> SmPC of [2] of EMA

Fatigue, dizziness, and asthenia have been reported in some patients taking BRUKINSA and should be considered when assessing a patient's ability to drive or operate machines.

Ability to drive, ziconotide [2] ---> SmPC of [2] of EMA

Ziconotide may cause confusion, somnolence and other neurological adverse reactions

Ability to drive, zidovudine

The ability to drive and use machines may be impaired

Ability to drive, ziprasidone

Somnolence may occur

Ability to drive, zofenopril

Debility, dizziness or fatigue may occur

Ability to drive, zoledronate [2] ---> SmPC of [2] of EMA

Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines

Ability to drive, zoledronic acid [2] ---> SmPC of [2] of EMA

Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines

Ability to drive, zolmitriptan [2] ---> SmPC of [2] of eMC

Caution is recommended in patients performing skilled tasks (e.g. driving or operating machinery) as drowsiness and other symptoms may occur during a migraine attack.

Ability to drive, zolpidem [2] ---> SmPC of [2] of eMC

Vehicle drivers and machine operators should be warned that, as with other hypnotics, there may be a possible risk of drowsiness the morning after therapy.

Ability to drive, zonisamide [2] ---> SmPC of [2] of EMA

Some patients may experience drowsiness or difficulty with concentration, particularly early in treatment or after a dose increase

Ability to drive, zopiclone [2] ---> SmPC of [2] of eMC

Although residual effects are rare and generally of minor significance, patients should be advised not to drive or operate machinery the day after treatment

Ability to drive, zotepine

Changes in the ability to react

Ability to drive, zuclopenthixol [2] ---> SmPC of [2] of eMC

Alertness may be impaired, especially at the start of treatment, or following the consumption of alcohol